{
  "id": "8c6b31eb-4cad-4b8a-b994-655169f99479",
  "title": "Psilocybin treatment extends cellular lifespan, improves survival of aged mice",
  "link": "https://www.nature.com/articles/s41514-025-00244-x",
  "description": "Article URL: https://www.nature.com/articles/s41514-025-00244-x Comments URL: https://news.ycombinator.com/item?id=44527358 Points: 12 # Comments: 1",
  "author": "pseudolus",
  "published": "Fri, 11 Jul 2025 00:50:13 +0000",
  "source": "https://hnrss.org/frontpage",
  "categories": null,
  "byline": "Hecker, Louise",
  "length": 34652,
  "excerpt": "Psilocybin, the naturally occurring psychedelic compound produced by hallucinogenic mushrooms, has received attention due to considerable clinical evidence for its therapeutic potential to treat various psychiatric and neurodegenerative indications. However, the underlying molecular mechanisms remain enigmatic, and few studies have explored its systemic impacts. We provide the first experimental evidence that psilocin (the active metabolite of psilocybin) treatment extends cellular lifespan and psilocybin treatment promotes increased longevity in aged mice, suggesting that psilocybin may be a potent geroprotective agent.",
  "siteName": "Nature",
  "favicon": "https://www.nature.com/static/images/favicons/nature/apple-touch-icon-f39cb19454.png",
  "text": "IntroductionTo date, \u003e150 clinical studies with psilocybin have been completed or are ongoing for various clinical indications, including psychiatric (anxiety, depression, addiction), neurodegenerative (Alzheimer’s), pain, and more1,2,3. Human studies have demonstrated that a single-dose of psilocybin can improve debilitating physical and psychological symptoms—with durable effects (up to ~5 years)4,5. Despite considerable clinical evidence supporting the therapeutic benefits of psilocybin, the molecular mechanisms responsible for these impacts remain enigmatic. Studies with psilocybin have predominantly focused on neurological impacts and/or behavioral outcomes; few studies have evaluated alternative or systemic mechanisms which may also contribute to its beneficial effects. The “psilocybin-telomere hypothesis”6 postulates that psilocybin interventions may quantifiably impact telomere length, which offers a potential explanation for its efficacy across a wide range of clinical indications. This hypothesis is based on a large corpus of studies linking mental health biological aging markers6. Accumulating evidence indicate that clinical depression accelerates aging and telomere shortening7,8,9. Positive mental psychological states are associated with longer telomeres, whereas negative psychological conditions (e.g. chronic stress, anxiety, and depression) are associated with telomere attrition7,10,11,12,13. Given the clinical evidence supporting the efficacy of psilocybin for these conditions, it is plausible that psilocybin may impact telomere length. However, no prior studies have experimentally investigated the direct impact of psilocybin on biological aging.To evaluate the impact of psilocybin on cellular aging, we employed a validated model of replicative senescence using human fetal lung fibroblasts14. For all in vitro studies, we used psilocin (the active metabolite of psilocybin), which is formed when psilocybin is broken down after ingestion. Cells were serially passaged with media containing psilocin or vehicle until they reached replicative senescence. Psilocin treatment (10 μM) resulted in a 29% extension of cellular lifespan, characterized by delayed exhaustion of proliferative potential, increased cumulative population doublings, and decreased population doubling time, compared to vehicle (Fig. 1A–F). Results were more striking using a higher dose of psilocin in the same cell type (100 μM treatment led to a 57% extension in cellular lifespan; Supplementary Fig. 1A–F). Induction of senescence occurred in both vehicle and psilocin-treated cells, as both groups reached exhaustion of their proliferative potential (no evidence of oncogenic transformation was observed), however the onset of senescence was delayed in psilocin-treated cells (Fig. 1A). Further, compared to vehicle, psilocin-treated cells exhibited decreased βgal activity (Fig. 1G–H). These results were consistent with dose-dependent reductions in markers of cell cycle arrest (p21, p16), and increased markers of proliferation (PCNA) and DNA replication (pRB) (Fig. 1I). Compared to vehicle, psilocin treatment also led to elevated sirtuin1 (SIRT1; a critical role in regulating cellular aging, metabolism, and stress-responses) and decreased Growth Arrest and DNA Damage-inducible 45 alpha (GADD45a) levels, suggesting reduced DNA damage (Fig. 1I). Psilocin treatment also reduced oxidative stress levels in a dose-dependent manner (Fig. 1J), which was associated with decreased levels of NADPH oxidase-4 (Nox4, a master regulator of oxidant production) and increased nuclear factor erythroid 2-related factor 2 (Nrf2, a master regulator of antioxidant responses) (Fig. 1I). Overall, these results suggest that the in vitro impacts of psilocin are dose-dependent, with higher dosing ultimately leading to greater cellular life extension. To further validate these findings, we repeated these studies with a different cell type (adult human skin fibroblasts); 100 μM psilocin treatment increased cellular lifespan by 51%, which was accompanied by reduced senescence and decreased oxidative stress levels (Supplementary Fig. 2). To investigate other potential mechanisms by which psilocin contributes to increased lifespan, we also evaluated the impact on telomere length (reductions in telomere length is a hallmark of cellular aging). As expected, senescent vehicle-treated cells exhibited reduced telomere length compared to young control cells (Fig. 1K). In contrast, telomere length was preserved in psilocin-treated age-matched cells (Fig. 1K). In summary, these data suggest that psilocin impacts signaling pathways associated with cellular aging, which ultimately delayed the onset of senescence and increased cellular lifespan.Fig. 1: Psilocin treatment extends cellular lifespan.Human lung fibroblasts were treated continuously with vehicle (DMSO 0.02%) or 10 µM psilocin until they reached replicative senescence. A Cumulative population doubling curves; arrows indicate time point when cells reach replicative senescence (n = 4 technical replicates). B The area under the curve (AUC) was calculated using the sum of trapeze areas for each time point intervals (n = 4 technical replicates). C Cumulative population doublings at the onset of senescence (n = 4 technical replicates). D Population doubling time comparing young cells (0–4 days) vs. aged cells (60–63 days) post-treatment. Groups were compared using 2-way ANOVA (n = 4 technical replicates). E Cumulative cell number over cellular lifespan. F Table showcasing cellular lifespan population doublings and lifespan extension. Extension refers to the number of additional population doublings of psilocin-treated cells vs. vehicle, which is also shown as a percent increase relative to vehicle-treated cells. G, H Senescence was assessed at 42 days post-treatment by senescence-associated β-galactosidase (β-gal) staining; scale bar = 70 µm (G) and quantitative assessment of β-gal activity (n = 5 technical replicates) (H). I Western blot demonstrating dose-dependent alterations in protein expression of age-associated markers. J Reactive oxygen species (ROS) production was evaluated by Amplex Red assay (n = 3 technical replicates). K Average telomere length was assessed by RT-PCR (n = 4 technical replicates) and is expressed as kilobase pairs per chromosomal end. All values are shown as mean ± SD. Unless otherwise stated, comparisons were made using two-sided unpaired t-tests with unequal variance.; *p \u003c 0.05, **p \u003c 0.01, ***p \u003c 0.001, ****p \u003c 0.0001, ns not significant.Full size imageTo evaluate the impact of psilocybin on longevity in vivo, aged (19 month) female mice were treated with vehicle or psilocybin once/month for 10 months (Fig. 2A); mice were initially given a low-dose (5 mg/kg) for the first treatment followed monthly high-dose (15 mg/kg) treatment for a total of 10 treatments. We elected to utilize 19-month old mice, which is roughly equivalent to 60–65 human years, in order to evaluate its therapeutic potential as a clinically-relevant anti-aging intervention. Within 30 min post-treatment, mice exhibited increased head-twitch response (data not shown), which is a well-established behavioral indicator of hallucinogenic impacts of psilocybin in mice15. Both psilocybin and vehicle groups exhibited some loss in body weight from the start to end of the treatment protocol, however weight loss was not significantly different in vehicle- vs. psilocybin-treated mice (Supplementary Fig. 3). Notably, psilocybin treated mice demonstrated significantly higher survival (80%), compared to vehicle (50%) (Fig. 2B). Although not quantitatively measured, psilocybin-treated mice exhibited phenotypic improvements in overall fur quality, including hair growth and reductions in white hair compared to vehicle-treated mice (Fig. 2C). In summary, we provide the first experimental evidence demonstrating that psilocybin treatment can enhance survival in aged mice.Fig. 2: Psilocybin treatment in aged mice extends lifespan.C57BL/6J aged (19 month) female mice were treated with vehicle (n = 28) or psilocybin (n = 30) by oral gavage. Mice were given a lower dose (5 mg/kg) of psilocybin in month 1, followed by monthly dosing with high dose (15 mg/kg). At 10 months post-initial treatment, when the first group of mice reached median survival, all were euthanized. A Schematic diagram of treatment protocol. B Kaplan–Meier survival curve over the 10-month treatment duration, showing vehicle-treated (n = 14 out of 28) vs. psilocybin-treated (n = 24 out of 30) mice; *p = 0.014 using the Log-rank Mantel–Cox test. C Representative images of mice prior to treatment (19 month) and after the final treatment (28 month) with vehicle or psilocybin. Red arrows indicate regions where hair growth and/or hair color changes were observed.Full size imagePsilocybin is a potent serotonergic agonist that interacts with the serotonin receptor (5-HT2A) and other 5-HT receptor subtypes. Notably, the 5-HT2A receptor is expressed in multiple organs and cell types (including fibroblasts, neurons, cardiomyocytes, endothelial, epithelial, macrophages, and T-cells)16. A recent study demonstrated that 5-HT2A stimulation in cortical neurons induced SIRT1-dependent expression of antioxidant enzymes, which led to reduced oxidative stress and neuroprotection17. SIRT1 is a key regulator of senescence, and overexpression of SIRT1 has been shown to extend organismal lifespan in C. elegans and mice18. Here, we demonstrate that psilocin increased SIRT1 expression in cells, suggesting a potential mechanism by which psilocybin delays senescence and promotes longevity. This study provides the first experimental evidence suggesting that psilocybin may impact multiple hallmarks of aging, including delayed senescence, preservation of telomere length, enhanced DNA stability (via increased DNA-damage responses such as GADD45a), and/or it could reduce aberrant intercellular communication (via decreased oxidative stress and subsequent signaling). Future studies are warranted to further elucidate the impacts of psilocybin on age-related pathways and the molecular mechanisms responsible for its systemic effects (including 5-HT-dependent and/or -independent mechanisms). Prior studies have demonstrated that the long-lasting impacts of psychedelic treatments may be due to epigenomic-driven alterations, including chromatin remodeling and DNA methylation19,20,21. It is possible that psilocybin may also mediate epigenetic changes which contribute to the observed geroprotective effects; such studies warrant investigation. However, regulatory barriers imposed by its schedule I designation along with the limited availability of federal funding for psilocybin research remain significant obstacles that have hindered research progress22,23; thus, the mechanisms underlying its potential therapeutic benefits remain poorly understood.Our study provides the first experimental evidence demonstrating that psilocybin impacts hallmarks of aging, supporting the previously proposed “psilocybin-telomere hypothesis”6. We demonstrate that psilocin/psilocybin treatment extends both cellular and animal lifespan (even when treatment is initiated late in life). An effective anti-aging treatment that could be administered to adults during late life could have significant clinical potential. The dose utilized in mice was modeled based on a clinical trial in patients ranging from 29 and 70 years (three patients were \u003e65 years), where no serious adverse events were reported at the study endpoint or the post-study follow-up (98 days)24; These findings support the feasibility of psilocybin treatment in older adults. Further, the FDA’s designation of psilocybin as a “breakthrough therapy” underscores its safety profile, as minimal adverse effects have been reported25,26,27,28. However, additional studies are warranted to identify optimized protocols for therapeutic efficacy, including the age of treatment initiation, frequency and dose of treatments, and to determine if treatment impacts maximal lifespan. Would earlier intervention yield greater therapeutic benefits, and/or is there a threshold in older age beyond which psilocybin fails to provide efficacy? Although some studies have reported sex-specific effects of psilocybin in rodents, the existing literature offers limited and inconsistent evidence regarding sex-based pharmacodynamic differences29,30,31. Accordingly, we employed a single-sex design to minimize potential confounding variables associated with sex-based biological differences and to ensure reproducibility in this initial in vivo investigation. Future studies are warranted to evaluate sex-specific therapeutic and mechanistic effects of psilocybin. Our in vitro studies suggest that psilocin-mediated cellular lifespan extension did not result in oncogenic transformation, as psilocin-treated cells did reach replicative senescence and exhaustion of proliferative potential. However, it could be argued that delayed exhaustion of proliferative potential and/or senescence could impact oncogenesis or cancer progression. Future research should rigorously assess the potential impacts of long-term psilocybin treatment in vivo on cancer incidence and/or progression. Few studies have evaluated the impacts of long-term prolonged dosing.Beyond its neurological and psychological benefits, our findings suggest that psilocybin influences systemic aging processes, potentially explaining its long-lasting therapeutic effects across multiple disease indications. Although the impact of psilocybin on peripheral organs remains largely unexplored, these studies implicate untapped therapeutic potential for psilocybin’s systemic impacts. Psilocybin may represent a “disruptive” pharmacotherapy as a novel geroprotective agent to promote healthy aging and/or as a potential therapeutic intervention for age-related diseases.MethodsReagentsPsilocybin (catalog #14041) and psilocin (catalog # 11864) were obtained from Cayman Chemical (Ann Arbor, MI) under a DEA license. We purchased the following antibodies: GAPDH, RB, phosphor-RB, (Cell Signaling); Nox4, PCNA, p53, p21, and β-actin (Abcam); p16 (BD Biosciences); Secondary horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit antibodies (Bio-Rad). We purchased a Halt Protease and Phosphatase inhibitor cocktail (ThermoFisher Scientific). All other chemicals/reagents were purchased (Sigma) unless otherwise stated.Animal studiesAged (19-month-old) female C57BL/6J mice were obtained from The Jackson Laboratory and acclimated in the institutional animal facility for one month prior to study initiation. Mice were then randomly allocated to control and treatment groups to ensure balanced group assignments, including comparable average body weights across groups. The rationale for dosing regimen utilized was based on a number of factors. First, we sought to model high-dose used in a clinical study for chronic pain, where patients were administered a psychedelic dose (25 mg) of psilocybin24. Using the standard allometric scaling method32, a human dose of 25 mg of psilocybin translates to a mouse dose of 5.14 mg/kg; this informed our starting point for dosing. However, mice exhibit a significantly faster metabolic profile for psilocybin compared to humans, leading to a shorter half-life and more rapid systemic clearance of psilocin; the elimination half-life of psilocin is ~0.9 h in mice33 vs 1.8–3 h in humans34. Due to this rapid clearance in mice, a higher dose of 15 mg/kg was selected to ensure sufficient systemic exposure comparable to those observed in human clinical trials. It is also important to note that toxicology studies indicate that psilocybin is well tolerated in mice up to doses of 180–250 mg/kg35, which is well above the dose utilized in this study. Mice received a low-dose (5 mg/kg) initially for the first treatment to acclimate mice for long-term treatment, followed by monthly high-dose of psilocybin (15 mg/kg in sterile saline) or vehicle (sterile saline) via oral gavage (on conscious mice) once/month (10 treatments total) (Fig. 2A); all treatments were administered monthly between ~9:00am and 12pm. Mice received treatments from a stock concentration of drug (4 mg/ml in sterile saline); mice were weighed on each treatment day and received a gavage volume ranging from 100 to 200 μl (total volume), depending on their weight at the time of treatment. All mice were sacrificed once any group reached 50% mortality, signaling the end of the study per IACUC protocol. Mice were euthanized by CO2 inhalation followed by a secondary method to ensure death, in accordance with the American veterinary medical association (AVMA) guidelines for the euthanasia of animals and approved institutional IACUC protocols. Mice were monitored for body weight and signs of morbidity throughout the duration of the experiment. Mice were provided standard chow ad libitum and maintained under a 12:12-h light/dark cycle. Researchers were not blinded to group allocation during the experimental procedures or data analysis due to logistical constraints, including regulatory and safety protocols associated with handling psilocybin, a Schedule I controlled substance, as well as the exploratory nature of the study. All experiments and procedures involving animals were conducted in accordance with Institutional Animal Care and Use (IACUC) Committee guidelines at Emory University (PROTO202000138).Telomere length assayGenomic DNA was isolated from cells using the QIAwave DNA Blood \u0026 Tissue kit (QIAGEN). Quantitative RT-PCR was performed with genomic DNA using primers designed against human telomere sequence or a single copy reference gene (Human kit, ScienCell, Catalog #8918). The single copy reference (SCR) primer set recognizes and amplifies a 100 bp-long region on human chromosome 17, which serves as reference for data normalization; Amplification curves were compared to the reference control with a known telomere length.Cell cultureHuman fetal lung fibroblasts (IMR-90) were purchased (Coriell Cell Repositories) and adult skin fibroblasts were purchased (ATCC). IMR-90 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin. Skin fibroblasts were cultured in fibroblast basal media supplemented with 2% FBS, L-glutamine (7.5 mM), FGF (5 ng/ml), insulin (5 μg/ml), hydrocortisone (1 μg/ml), and ascorbic acid (50 μg/ml). All cells were purchased at passages 7–8 and expanded for 2–3 passages prior to initiating treatment protocols. Psilocin was dissolved in DMSO (50 mM stock) for in vitro studies.Population doublingCells were plated at a fixed density (1 × 106) and cultured in a T75 flask. Cells were counted using a TC20 cell counter (Bio-rad) and passaged every 3–4 days and re-plated (1 × 106) throughout the duration of the experiment (until cells reached replicative senescence). The number of population doublings (PD) was calculated. We quantified the differences of psilocin vs. vehicle treatment using the Area Under the Growth Curve (AUC), as an indicator of treatment effect on cell doubling36,37.Senescence assaysWe used β-galactosidase substrate for the quantitative assessment of cellular senescence (ThermoFisher Scientific), according to the manufacturer’s instructions. We also used a senescence detection kit designed to histochemically detect β-gal activity in cultured cells (Abcam).Western immunoblottingWe prepared cell lysates in RIPA buffer with Halt protease and phosphatase inhibitor, subjected them to SDS-PAGE under reducing conditions, and performed western immunoblotting as previously described. Lysates were quantitated using a Micro BCA Protein assay kit (Pierce) according to instructions. We used ECL western blotting substrate (Azure biosystems) and Azure C400 Imaging Systems (Azure biosystems) to detect specific immunoreactive signals.Reactive oxygen species (ROS) detectionHydrogen peroxide (H2O2) levels in cells was evaluated by Amplex Red assay kit (ThermoFisher Scientific). The fluorescence intensity was measured at 550 nm for excitation and emission in the range of 590 nm using the Synergy H1 Plate Reader (BioTek).Statistical analysisGraphs were generated and statistical analyses were performed with GraphPad Prism Software Version 10.4.1 (532) Boston, MA, USA. For all cell culture experiments (Fig. 1), population doubling levels were calculated based on direct cell counts performed in four technical replicates at each passage. These replicate values were used to compute the mean ± standard deviation (SD) for each time point. Data from other assays, including β-galactosidase activity, ROS production, and telomere length, were analyzed using 3–5 technical replicates per group, as specified in the figure legends. Statistical comparisons were performed using two-tailed unpaired t-tests with unequal variance, or two-way ANOVA where appropriate. For the animal survival study (Fig. 2), survival curves were analyzed using the log-rank Mantel–Cox test. To ensure uniform survival endpoint analysis, all mice were euthanized at 10 months post-initial treatment, when the first group reached median survival. A p-value less than 0.05 was considered statistically significant. Complete details of statistical tests, number of replicates (n), and significance thresholds are provided in figure legend. Data availabilityAll datasets generated and/or analyzed during the current study are publicly available within this manuscript or the supplemental material.ReferencesGoel, A. et al. Use of psychedelics for pain: a scoping review. Anesthesiology 139, 523–536 (2023).Article  PubMed  Google Scholar  Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330, 843–853 (2023).Article  CAS  PubMed  PubMed Central  Google Scholar  Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637–1648 (2022).Article  CAS  PubMed  Google Scholar  Dworkin, R. H. et al. If the doors of perception were cleansed, would chronic pain be relieved? Evaluating the benefits and risks of psychedelics. J. Pain. 23, 1666–1679 (2022).Article  PubMed  Google Scholar  Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C. \u0026 Davis, A. K. Long-term effects of psychedelic drugs: a systematic review. Neurosci. Biobehav. Rev. 113, 179–189 (2020).Article  CAS  PubMed  Google Scholar  Germann, C. B. The psilocybin-telomere hypothesis: an empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging. Med Hypotheses 134, 109406 (2020).Article  CAS  PubMed  Google Scholar  Wikgren, M. et al. Short telomeres in depression and the general population are associated with a hypocortisolemic state. Biol. Psychiatry 71, 294–300 (2012).Article  CAS  PubMed  Google Scholar  Wolkowitz, O. et al. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol. Psychiatry 17, 164–172 (2012).Article  CAS  PubMed  Google Scholar  Needham, B. et al. Depression, anxiety and telomere length in young adults: evidence from the National Health and Nutrition Examination Survey. Mol. Psychiatry 20, 520–528 (2015).Article  CAS  PubMed  Google Scholar  Malan, S., Hemmings, S., Kidd, M., Martin, L. \u0026 Seedat, S. Investigation of telomere length and psychological stress in rape victims. Depression Anxiety 28, 1081–1085 (2011).Article  CAS  PubMed  Google Scholar  Wolkowitz, O. M. et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress-preliminary findings. PloS One 6, e17837 (2011).Article  CAS  PubMed  PubMed Central  Google Scholar  Simon, N. M. et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol. Psychiatry 60, 432–435 (2006).Article  CAS  PubMed  Google Scholar  Okereke, O. I. et al. High phobic anxiety is related to lower leukocyte telomere length in women. PloS One 7, e40516 (2012).Article  CAS  PubMed  PubMed Central  Google Scholar  Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014).Article  Google Scholar  Fadahunsi, N. et al. Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. Transl. Psychiatry 12, 330 (2022).Article  CAS  PubMed  PubMed Central  Google Scholar  Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021).Article  CAS  PubMed  PubMed Central  Google Scholar  Fanibunda, S. E. et al. Serotonin regulates mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT(2A) receptor and SIRT1-PGC-1alpha axis. Proc. Natl. Acad. Sci. USA 116, 11028–11037 (2019).Article  CAS  PubMed  PubMed Central  Google Scholar  Chen, C., Zhou, M., Ge, Y. \u0026 Wang, X. SIRT1 and aging related signaling pathways. Mech. Ageing Dev. 187, 111215 (2020).Article  CAS  PubMed  Google Scholar  Inserra, A., Campanale, A., Rezai, T., Romualdi, P. \u0026 Rubino, T. Epigenetic mechanisms of rapid-acting antidepressants. Transl. Psychiatry 14, 359 (2024).Article  PubMed  PubMed Central  Google Scholar  de la Fuente Revenga, M. et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 37, 109836 (2021).Article  PubMed  Google Scholar  Inserra, A. et al. Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): impact on neurotropic, neurotrophic, and neuroplasticity signaling. Prog. Neuropsychopharmacol. Biol. Psychiatry 119, 110594 (2022).Article  CAS  PubMed  Google Scholar  Johnson, M. W., Griffiths, R. R., Hendricks, P. S. \u0026 Henningfield, J. E. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142, 143–166 (2018).Article  CAS  PubMed  PubMed Central  Google Scholar  Hall, W. The need for publicly funded research on therapeutic use of psychedelic drugs. World Psychiatry 20, 197–198 (2021).Article  PubMed  PubMed Central  Google Scholar  Palitsky, R., et al. A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers. Psychotherapy (Chic) (2025).Hasler, F., Grimberg, U., Benz, M. A., Huber, T. \u0026 Vollenweider, F. X. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study. Psychopharmacology 172, 145–156 (2004).Article  CAS  PubMed  Google Scholar  Johnson, M. W., Richards, W. A. \u0026 Griffiths, R. R. Human hallucinogen research: guidelines for safety. J. Psychopharmacol. 22, 603–620 (2008).Article  CAS  PubMed  PubMed Central  Google Scholar  Grinspoon, L. \u0026 Bakalar, J. B. Can drugs be used to enhance the psychotherapeutic process?. Am. J. Psychother. 40, 393–404 (1986).Article  CAS  PubMed  Google Scholar  Aaronson, B. S. \u0026 Osmond, H. Psychedelics: the uses and implications of hallucinogenic drugs (Doubleday Garden City, 1970).Tyls, F. et al. Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behav. Pharm. 27, 309–320 (2016).Article  CAS  Google Scholar  Effinger, D. P., Quadir, S. G., Ramage, M. C., Cone, M. G. \u0026 Herman, M. A. Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. Transl. Psychiatry 13, 119 (2023).Article  CAS  PubMed  PubMed Central  Google Scholar  Shao, L. X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535–2544 e2534 (2021).Article  CAS  PubMed  PubMed Central  Google Scholar  Nair, A. B. \u0026 Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27–31 (2016).Article  PubMed  PubMed Central  Google Scholar  Thomann, J. et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front. Pharm. 15, 1391689 (2024).Article  CAS  Google Scholar  Holze, F., Becker, A. M., Kolaczynska, K. E., Duthaler, U. \u0026 Liechti, M. E. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. Clin. Pharm. Ther. 113, 822–831 (2023).Article  CAS  Google Scholar  Zhuk, O. et al. Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice. Toxins7, 1018–1029 (2015).Article  CAS  PubMed  PubMed Central  Google Scholar  Duan, F. et al. Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. J. Immunol. Methods 382, 224–228 (2012).Article  CAS  PubMed  Google Scholar  Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W. \u0026 Sorger, P. K. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 9, 708–714 (2013).Article  CAS  PubMed  PubMed Central  Google Scholar  Download referencesAcknowledgementsWe would like to acknowledge Aaron Clippinger for igniting our interest in psilocybin. Research reported in this publication was supported and made possible by the Imagine, Innovate and Impact (I3) Award from the Emory School of Medicine (LH and AJZ) and through the Georgia CTSA NIH award (UL1-TR002378), and a grant from the Emory Woodruff Health Sciences Center for Health in Aging (LH and AJZ). LH also received funding support for effort from the Veterans Administration Health System grant (BX006003). C.C. was partially supported by CPRIT RP210227 and RP200504, NIH/NCI P30 shared resource grant CA125123, NIH/NIEHS P42 ES027725 and P30 ES030285.Author informationAuthors and AffiliationsDivision of Pulmonary, Allergy and Critical Care and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USAKosuke Kato, Jennifer M. Kleinhenz, Yoon-Joo Shin \u0026 Louise HeckerSection of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USAKosuke KatoDivision of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USAJennifer M. Kleinhenz \u0026 Louise HeckerDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USACristian CoarfaDivision of Palliative Medicine, Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA, USAAli J. ZarrabiAtlanta VA Healthcare System, Atlanta, GA, USALouise HeckerAuthorsKosuke KatoJennifer M. KleinhenzYoon-Joo ShinCristian CoarfaAli J. ZarrabiLouise HeckerContributionsL.H. conceived the project, supervised all studies, and drafted the manuscript. L.H., K.K., Y.J.S., and J.M.K. designed, conducted, and/or performed analyses for experiments. C.C. contributed to the statistical analyses. All authors contributed intellectual input to the overall project and with manuscript/figure preparation.Corresponding authorCorrespondence to Louise Hecker.Ethics declarations Competing interests The authors declare no competing interests. Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Supplementary informationRights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissionsAbout this articleCite this articleKato, K., Kleinhenz, J.M., Shin, YJ. et al. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging 11, 55 (2025). https://doi.org/10.1038/s41514-025-00244-xDownload citationReceived: 09 December 2024Accepted: 02 June 2025Published: 08 July 2025DOI: https://doi.org/10.1038/s41514-025-00244-x",
  "image": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41514-025-00244-x/MediaObjects/41514_2025_244_Fig1_HTML.png",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv\u003e\n                    \n                        \u003cdiv id=\"Sec1-section\" data-title=\"Introduction\"\u003e\u003ch2 id=\"Sec1\"\u003eIntroduction\u003c/h2\u003e\u003cdiv id=\"Sec1-content\"\u003e\u003cp\u003eTo date, \u0026gt;150 clinical studies with psilocybin have been completed or are ongoing for various clinical indications, including psychiatric (anxiety, depression, addiction), neurodegenerative (Alzheimer’s), pain, and more\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Goel, A. et al. Use of psychedelics for pain: a scoping review. Anesthesiology 139, 523–536 (2023).\" href=\"#ref-CR1\" id=\"ref-link-section-d51012261e534\"\u003e1\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330, 843–853 (2023).\" href=\"#ref-CR2\" id=\"ref-link-section-d51012261e534_1\"\u003e2\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 3\" title=\"Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637–1648 (2022).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR3\" id=\"ref-link-section-d51012261e537\"\u003e3\u003c/a\u003e\u003c/sup\u003e. Human studies have demonstrated that a single-dose of psilocybin can improve debilitating physical and psychological symptoms—with durable effects (up to ~5 years)\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 4\" title=\"Dworkin, R. H. et al. If the doors of perception were cleansed, would chronic pain be relieved? Evaluating the benefits and risks of psychedelics. J. Pain. 23, 1666–1679 (2022).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR4\" id=\"ref-link-section-d51012261e541\"\u003e4\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 5\" title=\"Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C. \u0026amp; Davis, A. K. Long-term effects of psychedelic drugs: a systematic review. Neurosci. Biobehav. Rev. 113, 179–189 (2020).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR5\" id=\"ref-link-section-d51012261e544\"\u003e5\u003c/a\u003e\u003c/sup\u003e. Despite considerable clinical evidence supporting the therapeutic benefits of psilocybin, the molecular mechanisms responsible for these impacts remain enigmatic. Studies with psilocybin have predominantly focused on neurological impacts and/or behavioral outcomes; few studies have evaluated alternative or systemic mechanisms which may also contribute to its beneficial effects. The “psilocybin-telomere hypothesis”\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 6\" title=\"Germann, C. B. The psilocybin-telomere hypothesis: an empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging. Med Hypotheses 134, 109406 (2020).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR6\" id=\"ref-link-section-d51012261e548\"\u003e6\u003c/a\u003e\u003c/sup\u003e postulates that psilocybin interventions may quantifiably impact telomere length, which offers a potential explanation for its efficacy across a wide range of clinical indications. This hypothesis is based on a large corpus of studies linking mental health biological aging markers\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 6\" title=\"Germann, C. B. The psilocybin-telomere hypothesis: an empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging. Med Hypotheses 134, 109406 (2020).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR6\" id=\"ref-link-section-d51012261e552\"\u003e6\u003c/a\u003e\u003c/sup\u003e. Accumulating evidence indicate that clinical depression accelerates aging and telomere shortening\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Wikgren, M. et al. Short telomeres in depression and the general population are associated with a hypocortisolemic state. Biol. Psychiatry 71, 294–300 (2012).\" href=\"#ref-CR7\" id=\"ref-link-section-d51012261e556\"\u003e7\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Wolkowitz, O. et al. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol. Psychiatry 17, 164–172 (2012).\" href=\"#ref-CR8\" id=\"ref-link-section-d51012261e556_1\"\u003e8\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 9\" title=\"Needham, B. et al. Depression, anxiety and telomere length in young adults: evidence from the National Health and Nutrition Examination Survey. Mol. Psychiatry 20, 520–528 (2015).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR9\" id=\"ref-link-section-d51012261e559\"\u003e9\u003c/a\u003e\u003c/sup\u003e. Positive mental psychological states are associated with longer telomeres, whereas negative psychological conditions (e.g. chronic stress, anxiety, and depression) are associated with telomere attrition\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 7\" title=\"Wikgren, M. et al. Short telomeres in depression and the general population are associated with a hypocortisolemic state. Biol. Psychiatry 71, 294–300 (2012).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR7\" id=\"ref-link-section-d51012261e564\"\u003e7\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Malan, S., Hemmings, S., Kidd, M., Martin, L. \u0026amp; Seedat, S. Investigation of telomere length and psychological stress in rape victims. Depression Anxiety 28, 1081–1085 (2011).\" href=\"#ref-CR10\" id=\"ref-link-section-d51012261e567\"\u003e10\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Wolkowitz, O. M. et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress-preliminary findings. PloS One 6, e17837 (2011).\" href=\"#ref-CR11\" id=\"ref-link-section-d51012261e567_1\"\u003e11\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Simon, N. M. et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol. Psychiatry 60, 432–435 (2006).\" href=\"#ref-CR12\" id=\"ref-link-section-d51012261e567_2\"\u003e12\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 13\" title=\"Okereke, O. I. et al. High phobic anxiety is related to lower leukocyte telomere length in women. PloS One 7, e40516 (2012).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR13\" id=\"ref-link-section-d51012261e570\"\u003e13\u003c/a\u003e\u003c/sup\u003e. Given the clinical evidence supporting the efficacy of psilocybin for these conditions, it is plausible that psilocybin may impact telomere length. However, no prior studies have experimentally investigated the direct impact of psilocybin on biological aging.\u003c/p\u003e\u003cp\u003eTo evaluate the impact of psilocybin on cellular aging, we employed a validated model of replicative senescence using human fetal lung fibroblasts\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 14\" title=\"Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR14\" id=\"ref-link-section-d51012261e577\"\u003e14\u003c/a\u003e\u003c/sup\u003e. For all in vitro studies, we used psilocin (the active metabolite of psilocybin), which is formed when psilocybin is broken down after ingestion. Cells were serially passaged with media containing psilocin or vehicle until they reached replicative senescence. Psilocin treatment (10 μM) resulted in a 29% extension of cellular lifespan, characterized by delayed exhaustion of proliferative potential, increased cumulative population doublings, and decreased population doubling time, compared to vehicle (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1A–F\u003c/a\u003e). Results were more striking using a higher dose of psilocin in the same cell type (100 μM treatment led to a 57% extension in cellular lifespan; Supplementary Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#MOESM1\"\u003e1A–F\u003c/a\u003e). Induction of senescence occurred in both vehicle and psilocin-treated cells, as both groups reached exhaustion of their proliferative potential (no evidence of oncogenic transformation was observed), however the onset of senescence was delayed in psilocin-treated cells (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1A\u003c/a\u003e). Further, compared to vehicle, psilocin-treated cells exhibited decreased βgal activity (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1G–H\u003c/a\u003e). These results were consistent with dose-dependent reductions in markers of cell cycle arrest (p21, p16), and increased markers of proliferation (PCNA) and DNA replication (pRB) (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1I\u003c/a\u003e). Compared to vehicle, psilocin treatment also led to elevated sirtuin1 (SIRT1; a critical role in regulating cellular aging, metabolism, and stress-responses) and decreased Growth Arrest and DNA Damage-inducible 45 alpha (GADD45a) levels, suggesting reduced DNA damage (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1I\u003c/a\u003e). Psilocin treatment also reduced oxidative stress levels in a dose-dependent manner (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1J\u003c/a\u003e), which was associated with decreased levels of NADPH oxidase-4 (Nox4, a master regulator of oxidant production) and increased nuclear factor erythroid 2-related factor 2 (Nrf2, a master regulator of antioxidant responses) (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1I\u003c/a\u003e). Overall, these results suggest that the in vitro impacts of psilocin are dose-dependent, with higher dosing ultimately leading to greater cellular life extension. To further validate these findings, we repeated these studies with a different cell type (adult human skin fibroblasts); 100 μM psilocin treatment increased cellular lifespan by 51%, which was accompanied by reduced senescence and decreased oxidative stress levels (Supplementary Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#MOESM1\"\u003e2\u003c/a\u003e). To investigate other potential mechanisms by which psilocin contributes to increased lifespan, we also evaluated the impact on telomere length (reductions in telomere length is a hallmark of cellular aging). As expected, senescent vehicle-treated cells exhibited reduced telomere length compared to young control cells (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1K\u003c/a\u003e). In contrast, telomere length was preserved in psilocin-treated age-matched cells (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1K\u003c/a\u003e). In summary, these data suggest that psilocin impacts signaling pathways associated with cellular aging, which ultimately delayed the onset of senescence and increased cellular lifespan.\u003c/p\u003e\u003cdiv data-test=\"figure\" data-container-section=\"figure\" id=\"figure-1\" data-title=\"Psilocin treatment extends cellular lifespan.\"\u003e\u003cfigure\u003e\u003cfigcaption\u003e\u003cb id=\"Fig1\" data-test=\"figure-caption-text\"\u003eFig. 1: Psilocin treatment extends cellular lifespan.\u003c/b\u003e\u003c/figcaption\u003e\u003cdiv\u003e\u003cdiv\u003e\u003ca data-test=\"img-link\" data-track=\"click\" data-track-label=\"image\" data-track-action=\"view figure\" href=\"https://www.nature.com/articles/s41514-025-00244-x/figures/1\" rel=\"nofollow\"\u003e\u003cpicture\u003e\u003csource type=\"image/webp\" srcset=\"https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41514-025-00244-x/MediaObjects/41514_2025_244_Fig1_HTML.png?as=webp\"/\u003e\u003cimg aria-describedby=\"Fig1\" src=\"https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41514-025-00244-x/MediaObjects/41514_2025_244_Fig1_HTML.png\" alt=\"figure 1\" loading=\"lazy\" width=\"685\" height=\"882\"/\u003e\u003c/picture\u003e\u003c/a\u003e\u003c/div\u003e\u003cp\u003eHuman lung fibroblasts were treated continuously with vehicle (DMSO 0.02%) or 10 µM psilocin until they reached replicative senescence. \u003cb\u003eA\u003c/b\u003e Cumulative population doubling curves; arrows indicate time point when cells reach replicative senescence (\u003ci\u003en\u003c/i\u003e = 4 technical replicates). \u003cb\u003eB\u003c/b\u003e The area under the curve (AUC) was calculated using the sum of trapeze areas for each time point intervals (\u003ci\u003en\u003c/i\u003e = 4 technical replicates). \u003cb\u003eC\u003c/b\u003e Cumulative population doublings at the onset of senescence (\u003ci\u003en\u003c/i\u003e = 4 technical replicates). \u003cb\u003eD\u003c/b\u003e Population doubling time comparing young cells (0–4 days) vs. aged cells (60–63 days) post-treatment. Groups were compared using 2-way ANOVA (\u003ci\u003en\u003c/i\u003e = 4 technical replicates). \u003cb\u003eE\u003c/b\u003e Cumulative cell number over cellular lifespan. \u003cb\u003eF\u003c/b\u003e Table showcasing cellular lifespan population doublings and lifespan extension. Extension refers to the number of additional population doublings of psilocin-treated cells vs. vehicle, which is also shown as a percent increase relative to vehicle-treated cells. \u003cb\u003eG\u003c/b\u003e, \u003cb\u003eH\u003c/b\u003e Senescence was assessed at 42 days post-treatment by senescence-associated β-galactosidase (β-gal) staining; scale bar = 70 µm (\u003cb\u003eG\u003c/b\u003e) and quantitative assessment of β-gal activity (\u003ci\u003en\u003c/i\u003e = 5 technical replicates) (\u003cb\u003eH\u003c/b\u003e). \u003cb\u003eI\u003c/b\u003e Western blot demonstrating dose-dependent alterations in protein expression of age-associated markers. \u003cb\u003eJ\u003c/b\u003e Reactive oxygen species (ROS) production was evaluated by Amplex Red assay (\u003ci\u003en\u003c/i\u003e = 3 technical replicates). \u003cb\u003eK\u003c/b\u003e Average telomere length was assessed by RT-PCR (\u003ci\u003en\u003c/i\u003e = 4 technical replicates) and is expressed as kilobase pairs per chromosomal end. All values are shown as mean ± SD. Unless otherwise stated, comparisons were made using two-sided unpaired \u003ci\u003et\u003c/i\u003e-tests with unequal variance.; *\u003ci\u003ep\u003c/i\u003e \u0026lt; 0.05, **\u003ci\u003ep\u003c/i\u003e \u0026lt; 0.01, ***\u003ci\u003ep\u003c/i\u003e \u0026lt; 0.001, ****\u003ci\u003ep\u003c/i\u003e \u0026lt; 0.0001, ns not significant.\u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003ca data-test=\"article-link\" data-track=\"click\" data-track-label=\"button\" data-track-action=\"view figure\" href=\"https://www.nature.com/articles/s41514-025-00244-x/figures/1\" data-track-dest=\"link:Figure1 Full size image\" aria-label=\"Full size image figure 1\" rel=\"nofollow\"\u003e\u003cspan\u003eFull size image\u003c/span\u003e\u003c/a\u003e\u003c/p\u003e\u003c/figure\u003e\u003c/div\u003e\u003cp\u003eTo evaluate the impact of psilocybin on longevity in vivo, aged (19 month) female mice were treated with vehicle or psilocybin once/month for 10 months (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig2\"\u003e2A\u003c/a\u003e); mice were initially given a low-dose (5 mg/kg) for the first treatment followed monthly high-dose (15 mg/kg) treatment for a total of 10 treatments. We elected to utilize 19-month old mice, which is roughly equivalent to 60–65 human years, in order to evaluate its therapeutic potential as a clinically-relevant anti-aging intervention. Within 30 min post-treatment, mice exhibited increased head-twitch response (data not shown), which is a well-established behavioral indicator of hallucinogenic impacts of psilocybin in mice\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 15\" title=\"Fadahunsi, N. et al. Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. Transl. Psychiatry 12, 330 (2022).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR15\" id=\"ref-link-section-d51012261e721\"\u003e15\u003c/a\u003e\u003c/sup\u003e. Both psilocybin and vehicle groups exhibited some loss in body weight from the start to end of the treatment protocol, however weight loss was not significantly different in vehicle- vs. psilocybin-treated mice (Supplementary Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#MOESM1\"\u003e3\u003c/a\u003e). Notably, psilocybin treated mice demonstrated significantly higher survival (80%), compared to vehicle (50%) (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig2\"\u003e2B\u003c/a\u003e). Although not quantitatively measured, psilocybin-treated mice exhibited phenotypic improvements in overall fur quality, including hair growth and reductions in white hair compared to vehicle-treated mice (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig2\"\u003e2C\u003c/a\u003e). In summary, we provide the first experimental evidence demonstrating that psilocybin treatment can enhance survival in aged mice.\u003c/p\u003e\u003cdiv data-test=\"figure\" data-container-section=\"figure\" id=\"figure-2\" data-title=\"Psilocybin treatment in aged mice extends lifespan.\"\u003e\u003cfigure\u003e\u003cfigcaption\u003e\u003cb id=\"Fig2\" data-test=\"figure-caption-text\"\u003eFig. 2: Psilocybin treatment in aged mice extends lifespan.\u003c/b\u003e\u003c/figcaption\u003e\u003cdiv\u003e\u003cdiv\u003e\u003ca data-test=\"img-link\" data-track=\"click\" data-track-label=\"image\" data-track-action=\"view figure\" href=\"https://www.nature.com/articles/s41514-025-00244-x/figures/2\" rel=\"nofollow\"\u003e\u003cpicture\u003e\u003csource type=\"image/webp\" srcset=\"https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41514-025-00244-x/MediaObjects/41514_2025_244_Fig2_HTML.png?as=webp\"/\u003e\u003cimg aria-describedby=\"Fig2\" src=\"https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41514-025-00244-x/MediaObjects/41514_2025_244_Fig2_HTML.png\" alt=\"figure 2\" loading=\"lazy\" width=\"685\" height=\"921\"/\u003e\u003c/picture\u003e\u003c/a\u003e\u003c/div\u003e\u003cp\u003eC57BL/6J aged (19 month) female mice were treated with vehicle (\u003ci\u003en\u003c/i\u003e = 28) or psilocybin (\u003ci\u003en\u003c/i\u003e = 30) by oral gavage. Mice were given a lower dose (5 mg/kg) of psilocybin in month 1, followed by monthly dosing with high dose (15 mg/kg). At 10 months post-initial treatment, when the first group of mice reached median survival, all were euthanized. \u003cb\u003eA\u003c/b\u003e Schematic diagram of treatment protocol. \u003cb\u003eB\u003c/b\u003e Kaplan–Meier survival curve over the 10-month treatment duration, showing vehicle-treated (\u003ci\u003en\u003c/i\u003e = 14 out of 28) vs. psilocybin-treated (\u003ci\u003en\u003c/i\u003e = 24 out of 30) mice; *\u003ci\u003ep\u003c/i\u003e = 0.014 using the Log-rank Mantel–Cox test. \u003cb\u003eC\u003c/b\u003e Representative images of mice prior to treatment (19 month) and after the final treatment (28 month) with vehicle or psilocybin. Red arrows indicate regions where hair growth and/or hair color changes were observed.\u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003ca data-test=\"article-link\" data-track=\"click\" data-track-label=\"button\" data-track-action=\"view figure\" href=\"https://www.nature.com/articles/s41514-025-00244-x/figures/2\" data-track-dest=\"link:Figure2 Full size image\" aria-label=\"Full size image figure 2\" rel=\"nofollow\"\u003e\u003cspan\u003eFull size image\u003c/span\u003e\u003c/a\u003e\u003c/p\u003e\u003c/figure\u003e\u003c/div\u003e\u003cp\u003ePsilocybin is a potent serotonergic agonist that interacts with the serotonin receptor (5-HT\u003csub\u003e2A\u003c/sub\u003e) and other 5-HT receptor subtypes. Notably, the 5-HT\u003csub\u003e2A\u003c/sub\u003e receptor is expressed in multiple organs and cell types (including fibroblasts, neurons, cardiomyocytes, endothelial, epithelial, macrophages, and T-cells)\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 16\" title=\"Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR16\" id=\"ref-link-section-d51012261e787\"\u003e16\u003c/a\u003e\u003c/sup\u003e. A recent study demonstrated that 5-HT\u003csub\u003e2A\u003c/sub\u003e stimulation in cortical neurons induced SIRT1-dependent expression of antioxidant enzymes, which led to reduced oxidative stress and neuroprotection\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 17\" title=\"Fanibunda, S. E. et al. Serotonin regulates mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT(2A) receptor and SIRT1-PGC-1alpha axis. Proc. Natl. Acad. Sci. USA 116, 11028–11037 (2019).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR17\" id=\"ref-link-section-d51012261e793\"\u003e17\u003c/a\u003e\u003c/sup\u003e. SIRT1 is a key regulator of senescence, and overexpression of SIRT1 has been shown to extend organismal lifespan in C. elegans and mice\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 18\" title=\"Chen, C., Zhou, M., Ge, Y. \u0026amp; Wang, X. SIRT1 and aging related signaling pathways. Mech. Ageing Dev. 187, 111215 (2020).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR18\" id=\"ref-link-section-d51012261e798\"\u003e18\u003c/a\u003e\u003c/sup\u003e. Here, we demonstrate that psilocin increased SIRT1 expression in cells, suggesting a potential mechanism by which psilocybin delays senescence and promotes longevity. This study provides the first experimental evidence suggesting that psilocybin may impact multiple hallmarks of aging, including delayed senescence, preservation of telomere length, enhanced DNA stability (via increased DNA-damage responses such as GADD45a), and/or it could reduce aberrant intercellular communication (via decreased oxidative stress and subsequent signaling). Future studies are warranted to further elucidate the impacts of psilocybin on age-related pathways and the molecular mechanisms responsible for its systemic effects (including 5-HT-dependent and/or -independent mechanisms). Prior studies have demonstrated that the long-lasting impacts of psychedelic treatments may be due to epigenomic-driven alterations, including chromatin remodeling and DNA methylation\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Inserra, A., Campanale, A., Rezai, T., Romualdi, P. \u0026amp; Rubino, T. Epigenetic mechanisms of rapid-acting antidepressants. Transl. Psychiatry 14, 359 (2024).\" href=\"#ref-CR19\" id=\"ref-link-section-d51012261e802\"\u003e19\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"de la Fuente Revenga, M. et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 37, 109836 (2021).\" href=\"#ref-CR20\" id=\"ref-link-section-d51012261e802_1\"\u003e20\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 21\" title=\"Inserra, A. et al. Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): impact on neurotropic, neurotrophic, and neuroplasticity signaling. Prog. Neuropsychopharmacol. Biol. Psychiatry 119, 110594 (2022).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR21\" id=\"ref-link-section-d51012261e805\"\u003e21\u003c/a\u003e\u003c/sup\u003e. It is possible that psilocybin may also mediate epigenetic changes which contribute to the observed geroprotective effects; such studies warrant investigation. However, regulatory barriers imposed by its schedule I designation along with the limited availability of federal funding for psilocybin research remain significant obstacles that have hindered research progress\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 22\" title=\"Johnson, M. W., Griffiths, R. R., Hendricks, P. S. \u0026amp; Henningfield, J. E. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142, 143–166 (2018).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR22\" id=\"ref-link-section-d51012261e809\"\u003e22\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 23\" title=\"Hall, W. The need for publicly funded research on therapeutic use of psychedelic drugs. World Psychiatry 20, 197–198 (2021).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR23\" id=\"ref-link-section-d51012261e812\"\u003e23\u003c/a\u003e\u003c/sup\u003e; thus, the mechanisms underlying its potential therapeutic benefits remain poorly understood.\u003c/p\u003e\u003cp\u003eOur study provides the first experimental evidence demonstrating that psilocybin impacts hallmarks of aging, supporting the previously proposed “psilocybin-telomere hypothesis”\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 6\" title=\"Germann, C. B. The psilocybin-telomere hypothesis: an empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging. Med Hypotheses 134, 109406 (2020).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR6\" id=\"ref-link-section-d51012261e820\"\u003e6\u003c/a\u003e\u003c/sup\u003e. We demonstrate that psilocin/psilocybin treatment extends both cellular and animal lifespan (even when treatment is initiated late in life). An effective anti-aging treatment that could be administered to adults during late life could have significant clinical potential. The dose utilized in mice was modeled based on a clinical trial in patients ranging from 29 and 70 years (three patients were \u0026gt;65 years), where no serious adverse events were reported at the study endpoint or the post-study follow-up (98 days)\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 24\" title=\"Palitsky, R., et al. A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers. Psychotherapy (Chic) (2025).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR24\" id=\"ref-link-section-d51012261e824\"\u003e24\u003c/a\u003e\u003c/sup\u003e; These findings support the feasibility of psilocybin treatment in older adults. Further, the FDA’s designation of psilocybin as a “breakthrough therapy” underscores its safety profile, as minimal adverse effects have been reported\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Hasler, F., Grimberg, U., Benz, M. A., Huber, T. \u0026amp; Vollenweider, F. X. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study. Psychopharmacology 172, 145–156 (2004).\" href=\"#ref-CR25\" id=\"ref-link-section-d51012261e828\"\u003e25\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Johnson, M. W., Richards, W. A. \u0026amp; Griffiths, R. R. Human hallucinogen research: guidelines for safety. J. Psychopharmacol. 22, 603–620 (2008).\" href=\"#ref-CR26\" id=\"ref-link-section-d51012261e828_1\"\u003e26\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Grinspoon, L. \u0026amp; Bakalar, J. B. Can drugs be used to enhance the psychotherapeutic process?. Am. J. Psychother. 40, 393–404 (1986).\" href=\"#ref-CR27\" id=\"ref-link-section-d51012261e828_2\"\u003e27\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 28\" title=\"Aaronson, B. S. \u0026amp; Osmond, H. Psychedelics: the uses and implications of hallucinogenic drugs (Doubleday Garden City, 1970).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR28\" id=\"ref-link-section-d51012261e831\"\u003e28\u003c/a\u003e\u003c/sup\u003e. However, additional studies are warranted to identify optimized protocols for therapeutic efficacy, including the age of treatment initiation, frequency and dose of treatments, and to determine if treatment impacts maximal lifespan. Would earlier intervention yield greater therapeutic benefits, and/or is there a threshold in older age beyond which psilocybin fails to provide efficacy? Although some studies have reported sex-specific effects of psilocybin in rodents, the existing literature offers limited and inconsistent evidence regarding sex-based pharmacodynamic differences\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Tyls, F. et al. Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behav. Pharm. 27, 309–320 (2016).\" href=\"#ref-CR29\" id=\"ref-link-section-d51012261e835\"\u003e29\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Effinger, D. P., Quadir, S. G., Ramage, M. C., Cone, M. G. \u0026amp; Herman, M. A. Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. Transl. Psychiatry 13, 119 (2023).\" href=\"#ref-CR30\" id=\"ref-link-section-d51012261e835_1\"\u003e30\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 31\" title=\"Shao, L. X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535–2544 e2534 (2021).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR31\" id=\"ref-link-section-d51012261e838\"\u003e31\u003c/a\u003e\u003c/sup\u003e. Accordingly, we employed a single-sex design to minimize potential confounding variables associated with sex-based biological differences and to ensure reproducibility in this initial in vivo investigation. Future studies are warranted to evaluate sex-specific therapeutic and mechanistic effects of psilocybin. Our in vitro studies suggest that psilocin-mediated cellular lifespan extension did not result in oncogenic transformation, as psilocin-treated cells did reach replicative senescence and exhaustion of proliferative potential. However, it could be argued that delayed exhaustion of proliferative potential and/or senescence could impact oncogenesis or cancer progression. Future research should rigorously assess the potential impacts of long-term psilocybin treatment in vivo on cancer incidence and/or progression. Few studies have evaluated the impacts of long-term prolonged dosing.\u003c/p\u003e\u003cp\u003eBeyond its neurological and psychological benefits, our findings suggest that psilocybin influences systemic aging processes, potentially explaining its long-lasting therapeutic effects across multiple disease indications. Although the impact of psilocybin on peripheral organs remains largely unexplored, these studies implicate untapped therapeutic potential for psilocybin’s systemic impacts. Psilocybin may represent a “disruptive” pharmacotherapy as a novel geroprotective agent to promote healthy aging and/or as a potential therapeutic intervention for age-related diseases.\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Sec2-section\" data-title=\"Methods\"\u003e\u003ch2 id=\"Sec2\"\u003eMethods\u003c/h2\u003e\u003cdiv id=\"Sec2-content\"\u003e\u003ch3 id=\"Sec3\"\u003eReagents\u003c/h3\u003e\u003cp\u003ePsilocybin (catalog #14041) and psilocin (catalog # 11864) were obtained from Cayman Chemical (Ann Arbor, MI) under a DEA license. We purchased the following antibodies: GAPDH, RB, phosphor-RB, (Cell Signaling); Nox4, PCNA, p53, p21, and β-actin (Abcam); p16 (BD Biosciences); Secondary horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit antibodies (Bio-Rad). We purchased a Halt Protease and Phosphatase inhibitor cocktail (ThermoFisher Scientific). All other chemicals/reagents were purchased (Sigma) unless otherwise stated.\u003c/p\u003e\u003ch3 id=\"Sec4\"\u003eAnimal studies\u003c/h3\u003e\u003cp\u003eAged (19-month-old) female C57BL/6J mice were obtained from The Jackson Laboratory and acclimated in the institutional animal facility for one month prior to study initiation. Mice were then randomly allocated to control and treatment groups to ensure balanced group assignments, including comparable average body weights across groups. The rationale for dosing regimen utilized was based on a number of factors. First, we sought to model high-dose used in a clinical study for chronic pain, where patients were administered a psychedelic dose (25 mg) of psilocybin\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 24\" title=\"Palitsky, R., et al. A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers. Psychotherapy (Chic) (2025).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR24\" id=\"ref-link-section-d51012261e865\"\u003e24\u003c/a\u003e\u003c/sup\u003e. Using the standard allometric scaling method\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 32\" title=\"Nair, A. B. \u0026amp; Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27–31 (2016).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR32\" id=\"ref-link-section-d51012261e869\"\u003e32\u003c/a\u003e\u003c/sup\u003e, a human dose of 25 mg of psilocybin translates to a mouse dose of 5.14 mg/kg; this informed our starting point for dosing. However, mice exhibit a significantly faster metabolic profile for psilocybin compared to humans, leading to a shorter half-life and more rapid systemic clearance of psilocin; the elimination half-life of psilocin is ~0.9 h in mice\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 33\" title=\"Thomann, J. et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front. Pharm. 15, 1391689 (2024).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR33\" id=\"ref-link-section-d51012261e873\"\u003e33\u003c/a\u003e\u003c/sup\u003e vs 1.8–3 h in humans\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 34\" title=\"Holze, F., Becker, A. M., Kolaczynska, K. E., Duthaler, U. \u0026amp; Liechti, M. E. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. Clin. Pharm. Ther. 113, 822–831 (2023).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR34\" id=\"ref-link-section-d51012261e877\"\u003e34\u003c/a\u003e\u003c/sup\u003e. Due to this rapid clearance in mice, a higher dose of 15 mg/kg was selected to ensure sufficient systemic exposure comparable to those observed in human clinical trials. It is also important to note that toxicology studies indicate that psilocybin is well tolerated in mice up to doses of 180–250 mg/kg\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 35\" title=\"Zhuk, O. et al. Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice. Toxins7, 1018–1029 (2015).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR35\" id=\"ref-link-section-d51012261e881\"\u003e35\u003c/a\u003e\u003c/sup\u003e, which is well above the dose utilized in this study. Mice received a low-dose (5 mg/kg) initially for the first treatment to acclimate mice for long-term treatment, followed by monthly high-dose of psilocybin (15 mg/kg in sterile saline) or vehicle (sterile saline) via oral gavage (on conscious mice) once/month (10 treatments total) (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig2\"\u003e2A\u003c/a\u003e); all treatments were administered monthly between ~9:00am and 12pm. Mice received treatments from a stock concentration of drug (4 mg/ml in sterile saline); mice were weighed on each treatment day and received a gavage volume ranging from 100 to 200 μl (total volume), depending on their weight at the time of treatment. All mice were sacrificed once any group reached 50% mortality, signaling the end of the study per IACUC protocol. Mice were euthanized by CO\u003csub\u003e2\u003c/sub\u003e inhalation followed by a secondary method to ensure death, in accordance with the American veterinary medical association (AVMA) guidelines for the euthanasia of animals and approved institutional IACUC protocols. Mice were monitored for body weight and signs of morbidity throughout the duration of the experiment. Mice were provided standard chow ad libitum and maintained under a 12:12-h light/dark cycle. Researchers were not blinded to group allocation during the experimental procedures or data analysis due to logistical constraints, including regulatory and safety protocols associated with handling psilocybin, a Schedule I controlled substance, as well as the exploratory nature of the study. All experiments and procedures involving animals were conducted in accordance with Institutional Animal Care and Use (IACUC) Committee guidelines at Emory University (PROTO202000138).\u003c/p\u003e\u003ch3 id=\"Sec5\"\u003eTelomere length assay\u003c/h3\u003e\u003cp\u003eGenomic DNA was isolated from cells using the QIAwave DNA Blood \u0026amp; Tissue kit (QIAGEN). Quantitative RT-PCR was performed with genomic DNA using primers designed against human telomere sequence or a single copy reference gene (Human kit, ScienCell, Catalog #8918). The single copy reference (SCR) primer set recognizes and amplifies a 100 bp-long region on human chromosome 17, which serves as reference for data normalization; Amplification curves were compared to the reference control with a known telomere length.\u003c/p\u003e\u003ch3 id=\"Sec6\"\u003eCell culture\u003c/h3\u003e\u003cp\u003eHuman fetal lung fibroblasts (IMR-90) were purchased (Coriell Cell Repositories) and adult skin fibroblasts were purchased (ATCC). IMR-90 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin. Skin fibroblasts were cultured in fibroblast basal media supplemented with 2% FBS, L-glutamine (7.5 mM), FGF (5 ng/ml), insulin (5 μg/ml), hydrocortisone (1 μg/ml), and ascorbic acid (50 μg/ml). All cells were purchased at passages 7–8 and expanded for 2–3 passages prior to initiating treatment protocols. Psilocin was dissolved in DMSO (50 mM stock) for in vitro studies.\u003c/p\u003e\u003ch3 id=\"Sec7\"\u003ePopulation doubling\u003c/h3\u003e\u003cp\u003eCells were plated at a fixed density (1 × 10\u003csup\u003e6\u003c/sup\u003e) and cultured in a T75 flask. Cells were counted using a TC20 cell counter (Bio-rad) and passaged every 3–4 days and re-plated (1 × 10\u003csup\u003e6\u003c/sup\u003e) throughout the duration of the experiment (until cells reached replicative senescence). The number of population doublings (PD) was calculated. We quantified the differences of psilocin vs. vehicle treatment using the Area Under the Growth Curve (AUC), as an indicator of treatment effect on cell doubling\u003csup\u003e\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 36\" title=\"Duan, F. et al. Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. J. Immunol. Methods 382, 224–228 (2012).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR36\" id=\"ref-link-section-d51012261e920\"\u003e36\u003c/a\u003e,\u003ca data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 37\" title=\"Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W. \u0026amp; Sorger, P. K. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 9, 708–714 (2013).\" href=\"https://www.nature.com/articles/s41514-025-00244-x#ref-CR37\" id=\"ref-link-section-d51012261e923\"\u003e37\u003c/a\u003e\u003c/sup\u003e.\u003c/p\u003e\u003ch3 id=\"Sec8\"\u003eSenescence assays\u003c/h3\u003e\u003cp\u003eWe used β-galactosidase substrate for the quantitative assessment of cellular senescence (ThermoFisher Scientific), according to the manufacturer’s instructions. We also used a senescence detection kit designed to histochemically detect β-gal activity in cultured cells (Abcam).\u003c/p\u003e\u003ch3 id=\"Sec9\"\u003eWestern immunoblotting\u003c/h3\u003e\u003cp\u003eWe prepared cell lysates in RIPA buffer with Halt protease and phosphatase inhibitor, subjected them to SDS-PAGE under reducing conditions, and performed western immunoblotting as previously described. Lysates were quantitated using a Micro BCA Protein assay kit (Pierce) according to instructions. We used ECL western blotting substrate (Azure biosystems) and Azure C400 Imaging Systems (Azure biosystems) to detect specific immunoreactive signals.\u003c/p\u003e\u003ch3 id=\"Sec10\"\u003eReactive oxygen species (ROS) detection\u003c/h3\u003e\u003cp\u003eHydrogen peroxide (H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e) levels in cells was evaluated by Amplex Red assay kit (ThermoFisher Scientific). The fluorescence intensity was measured at 550 nm for excitation and emission in the range of 590 nm using the Synergy H1 Plate Reader (BioTek).\u003c/p\u003e\u003ch3 id=\"Sec11\"\u003eStatistical analysis\u003c/h3\u003e\u003cp\u003eGraphs were generated and statistical analyses were performed with GraphPad Prism Software \u003ci\u003eVersion 10.4.1 (532) Boston, MA, USA\u003c/i\u003e. For all cell culture experiments (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig1\"\u003e1\u003c/a\u003e), population doubling levels were calculated based on direct cell counts performed in four technical replicates at each passage. These replicate values were used to compute the mean ± standard deviation (SD) for each time point. Data from other assays, including β-galactosidase activity, ROS production, and telomere length, were analyzed using 3–5 technical replicates per group, as specified in the figure legends. Statistical comparisons were performed using two-tailed unpaired \u003ci\u003et\u003c/i\u003e-tests with unequal variance, or two-way ANOVA where appropriate. For the animal survival study (Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https://www.nature.com/articles/s41514-025-00244-x#Fig2\"\u003e2\u003c/a\u003e), survival curves were analyzed using the log-rank Mantel–Cox test. To ensure uniform survival endpoint analysis, all mice were euthanized at 10 months post-initial treatment, when the first group reached median survival. A \u003ci\u003ep\u003c/i\u003e-value less than 0.05 was considered statistically significant. Complete details of statistical tests, number of replicates (\u003ci\u003en\u003c/i\u003e), and significance thresholds are provided in figure legend.\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\n                    \n                \u003c/div\u003e\u003cdiv\u003e\n                \u003cdiv id=\"data-availability-section\" data-title=\"Data availability\"\u003e\u003ch2 id=\"data-availability\"\u003eData availability\u003c/h2\u003e\u003cp\u003eAll datasets generated and/or analyzed during the current study are publicly available within this manuscript or the supplemental material.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"MagazineFulltextArticleBodySuffix\" aria-labelledby=\"Bib1\" data-title=\"References\"\u003e\u003ch2 id=\"Bib1\"\u003eReferences\u003c/h2\u003e\u003cdiv data-container-section=\"references\" id=\"Bib1-content\"\u003e\u003col data-track-component=\"outbound reference\" data-track-context=\"references section\"\u003e\u003cli data-counter=\"1.\"\u003e\u003cp id=\"ref-CR1\"\u003eGoel, A. et al. Use of psychedelics for pain: a scoping review. \u003ci\u003eAnesthesiology\u003c/i\u003e \u003cb\u003e139\u003c/b\u003e, 523–536 (2023).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1097/ALN.0000000000004673\" data-track-item_id=\"10.1097/ALN.0000000000004673\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1097%2FALN.0000000000004673\" aria-label=\"Article reference 1\" data-doi=\"10.1097/ALN.0000000000004673\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=37698433\" aria-label=\"PubMed reference 1\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 1\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Use%20of%20psychedelics%20for%20pain%3A%20a%20scoping%20review\u0026amp;journal=Anesthesiology\u0026amp;doi=10.1097%2FALN.0000000000004673\u0026amp;volume=139\u0026amp;pages=523-536\u0026amp;publication_year=2023\u0026amp;author=Goel%2CA\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"2.\"\u003e\u003cp id=\"ref-CR2\"\u003eRaison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. \u003ci\u003eJAMA\u003c/i\u003e \u003cb\u003e330\u003c/b\u003e, 843–853 (2023).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1001/jama.2023.14530\" data-track-item_id=\"10.1001/jama.2023.14530\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1001%2Fjama.2023.14530\" aria-label=\"Article reference 2\" data-doi=\"10.1001/jama.2023.14530\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXhvVymurnI\" aria-label=\"CAS reference 2\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=37651119\" aria-label=\"PubMed reference 2\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472268\" aria-label=\"PubMed Central reference 2\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 2\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Single-dose%20psilocybin%20treatment%20for%20major%20depressive%20disorder%3A%20a%20randomized%20clinical%20trial\u0026amp;journal=JAMA\u0026amp;doi=10.1001%2Fjama.2023.14530\u0026amp;volume=330\u0026amp;pages=843-853\u0026amp;publication_year=2023\u0026amp;author=Raison%2CCL\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"3.\"\u003e\u003cp id=\"ref-CR3\"\u003eGoodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. \u003ci\u003eN. Engl. J. Med.\u003c/i\u003e \u003cb\u003e387\u003c/b\u003e, 1637–1648 (2022).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1056/NEJMoa2206443\" data-track-item_id=\"10.1056/NEJMoa2206443\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1056%2FNEJMoa2206443\" aria-label=\"Article reference 3\" data-doi=\"10.1056/NEJMoa2206443\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XivVOmu7rL\" aria-label=\"CAS reference 3\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=36322843\" aria-label=\"PubMed reference 3\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 3\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Single-dose%20psilocybin%20for%20a%20treatment-resistant%20episode%20of%20major%20depression\u0026amp;journal=N.%20Engl.%20J.%20Med.\u0026amp;doi=10.1056%2FNEJMoa2206443\u0026amp;volume=387\u0026amp;pages=1637-1648\u0026amp;publication_year=2022\u0026amp;author=Goodwin%2CGM\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"4.\"\u003e\u003cp id=\"ref-CR4\"\u003eDworkin, R. H. et al. If the doors of perception were cleansed, would chronic pain be relieved? Evaluating the benefits and risks of psychedelics. \u003ci\u003eJ. Pain.\u003c/i\u003e \u003cb\u003e23\u003c/b\u003e, 1666–1679 (2022).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.jpain.2022.05.003\" data-track-item_id=\"10.1016/j.jpain.2022.05.003\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.jpain.2022.05.003\" aria-label=\"Article reference 4\" data-doi=\"10.1016/j.jpain.2022.05.003\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=35643270\" aria-label=\"PubMed reference 4\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 4\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=If%20the%20doors%20of%20perception%20were%20cleansed%2C%20would%20chronic%20pain%20be%20relieved%3F%20Evaluating%20the%20benefits%20and%20risks%20of%20psychedelics\u0026amp;journal=J.%20Pain.\u0026amp;doi=10.1016%2Fj.jpain.2022.05.003\u0026amp;volume=23\u0026amp;pages=1666-1679\u0026amp;publication_year=2022\u0026amp;author=Dworkin%2CRH\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"5.\"\u003e\u003cp id=\"ref-CR5\"\u003eAday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C. \u0026amp; Davis, A. K. Long-term effects of psychedelic drugs: a systematic review. \u003ci\u003eNeurosci. Biobehav. Rev.\u003c/i\u003e \u003cb\u003e113\u003c/b\u003e, 179–189 (2020).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.neubiorev.2020.03.017\" data-track-item_id=\"10.1016/j.neubiorev.2020.03.017\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.neubiorev.2020.03.017\" aria-label=\"Article reference 5\" data-doi=\"10.1016/j.neubiorev.2020.03.017\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXmt1Gmsr0%3D\" aria-label=\"CAS reference 5\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=32194129\" aria-label=\"PubMed reference 5\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 5\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Long-term%20effects%20of%20psychedelic%20drugs%3A%20a%20systematic%20review\u0026amp;journal=Neurosci.%20Biobehav.%20Rev.\u0026amp;doi=10.1016%2Fj.neubiorev.2020.03.017\u0026amp;volume=113\u0026amp;pages=179-189\u0026amp;publication_year=2020\u0026amp;author=Aday%2CJS\u0026amp;author=Mitzkovitz%2CCM\u0026amp;author=Bloesch%2CEK\u0026amp;author=Davoli%2CCC\u0026amp;author=Davis%2CAK\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"6.\"\u003e\u003cp id=\"ref-CR6\"\u003eGermann, C. B. The psilocybin-telomere hypothesis: an empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging. \u003ci\u003eMed Hypotheses\u003c/i\u003e \u003cb\u003e134\u003c/b\u003e, 109406 (2020).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.mehy.2019.109406\" data-track-item_id=\"10.1016/j.mehy.2019.109406\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.mehy.2019.109406\" aria-label=\"Article reference 6\" data-doi=\"10.1016/j.mehy.2019.109406\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitVaqsL%2FL\" aria-label=\"CAS reference 6\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=31634774\" aria-label=\"PubMed reference 6\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 6\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=The%20psilocybin-telomere%20hypothesis%3A%20an%20empirically%20falsifiable%20prediction%20concerning%20the%20beneficial%20neuropsychopharmacological%20effects%20of%20psilocybin%20on%20genetic%20aging\u0026amp;journal=Med%20Hypotheses\u0026amp;doi=10.1016%2Fj.mehy.2019.109406\u0026amp;volume=134\u0026amp;publication_year=2020\u0026amp;author=Germann%2CCB\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"7.\"\u003e\u003cp id=\"ref-CR7\"\u003eWikgren, M. et al. Short telomeres in depression and the general population are associated with a hypocortisolemic state. \u003ci\u003eBiol. Psychiatry\u003c/i\u003e \u003cb\u003e71\u003c/b\u003e, 294–300 (2012).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.biopsych.2011.09.015\" data-track-item_id=\"10.1016/j.biopsych.2011.09.015\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.biopsych.2011.09.015\" aria-label=\"Article reference 7\" data-doi=\"10.1016/j.biopsych.2011.09.015\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xht1Oiur8%3D\" aria-label=\"CAS reference 7\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=22055018\" aria-label=\"PubMed reference 7\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 7\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Short%20telomeres%20in%20depression%20and%20the%20general%20population%20are%20associated%20with%20a%20hypocortisolemic%20state\u0026amp;journal=Biol.%20Psychiatry\u0026amp;doi=10.1016%2Fj.biopsych.2011.09.015\u0026amp;volume=71\u0026amp;pages=294-300\u0026amp;publication_year=2012\u0026amp;author=Wikgren%2CM\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"8.\"\u003e\u003cp id=\"ref-CR8\"\u003eWolkowitz, O. et al. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. \u003ci\u003eMol. Psychiatry\u003c/i\u003e \u003cb\u003e17\u003c/b\u003e, 164–172 (2012).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1038/mp.2010.133\" data-track-item_id=\"10.1038/mp.2010.133\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1038%2Fmp.2010.133\" aria-label=\"Article reference 8\" data-doi=\"10.1038/mp.2010.133\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhsVWhsLc%3D\" aria-label=\"CAS reference 8\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=21242992\" aria-label=\"PubMed reference 8\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 8\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Resting%20leukocyte%20telomerase%20activity%20is%20elevated%20in%20major%20depression%20and%20predicts%20treatment%20response\u0026amp;journal=Mol.%20Psychiatry\u0026amp;doi=10.1038%2Fmp.2010.133\u0026amp;volume=17\u0026amp;pages=164-172\u0026amp;publication_year=2012\u0026amp;author=Wolkowitz%2CO\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"9.\"\u003e\u003cp id=\"ref-CR9\"\u003eNeedham, B. et al. Depression, anxiety and telomere length in young adults: evidence from the National Health and Nutrition Examination Survey. \u003ci\u003eMol. Psychiatry\u003c/i\u003e \u003cb\u003e20\u003c/b\u003e, 520–528 (2015).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1038/mp.2014.89\" data-track-item_id=\"10.1038/mp.2014.89\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1038%2Fmp.2014.89\" aria-label=\"Article reference 9\" data-doi=\"10.1038/mp.2014.89\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC2M%2FntVaiug%3D%3D\" aria-label=\"CAS reference 9\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=25178165\" aria-label=\"PubMed reference 9\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 9\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Depression%2C%20anxiety%20and%20telomere%20length%20in%20young%20adults%3A%20evidence%20from%20the%20National%20Health%20and%20Nutrition%20Examination%20Survey\u0026amp;journal=Mol.%20Psychiatry\u0026amp;doi=10.1038%2Fmp.2014.89\u0026amp;volume=20\u0026amp;pages=520-528\u0026amp;publication_year=2015\u0026amp;author=Needham%2CB\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"10.\"\u003e\u003cp id=\"ref-CR10\"\u003eMalan, S., Hemmings, S., Kidd, M., Martin, L. \u0026amp; Seedat, S. Investigation of telomere length and psychological stress in rape victims. \u003ci\u003eDepression Anxiety\u003c/i\u003e \u003cb\u003e28\u003c/b\u003e, 1081–1085 (2011).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1002/da.20903\" data-track-item_id=\"10.1002/da.20903\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1002%2Fda.20903\" aria-label=\"Article reference 10\" data-doi=\"10.1002/da.20903\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsFCqs7rI\" aria-label=\"CAS reference 10\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=22065550\" aria-label=\"PubMed reference 10\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 10\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Investigation%20of%20telomere%20length%20and%20psychological%20stress%20in%20rape%20victims\u0026amp;journal=Depression%20Anxiety\u0026amp;doi=10.1002%2Fda.20903\u0026amp;volume=28\u0026amp;pages=1081-1085\u0026amp;publication_year=2011\u0026amp;author=Malan%2CS\u0026amp;author=Hemmings%2CS\u0026amp;author=Kidd%2CM\u0026amp;author=Martin%2CL\u0026amp;author=Seedat%2CS\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"11.\"\u003e\u003cp id=\"ref-CR11\"\u003eWolkowitz, O. M. et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress-preliminary findings. \u003ci\u003ePloS One\u003c/i\u003e \u003cb\u003e6\u003c/b\u003e, e17837 (2011).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1371/journal.pone.0017837\" data-track-item_id=\"10.1371/journal.pone.0017837\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1371%2Fjournal.pone.0017837\" aria-label=\"Article reference 11\" data-doi=\"10.1371/journal.pone.0017837\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXktl2rsbg%3D\" aria-label=\"CAS reference 11\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=21448457\" aria-label=\"PubMed reference 11\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063175\" aria-label=\"PubMed Central reference 11\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 11\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Leukocyte%20telomere%20length%20in%20major%20depression%3A%20correlations%20with%20chronicity%2C%20inflammation%20and%20oxidative%20stress-preliminary%20findings\u0026amp;journal=PloS%20One\u0026amp;doi=10.1371%2Fjournal.pone.0017837\u0026amp;volume=6\u0026amp;publication_year=2011\u0026amp;author=Wolkowitz%2COM\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"12.\"\u003e\u003cp id=\"ref-CR12\"\u003eSimon, N. M. et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. \u003ci\u003eBiol. Psychiatry\u003c/i\u003e \u003cb\u003e60\u003c/b\u003e, 432–435 (2006).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.biopsych.2006.02.004\" data-track-item_id=\"10.1016/j.biopsych.2006.02.004\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.biopsych.2006.02.004\" aria-label=\"Article reference 12\" data-doi=\"10.1016/j.biopsych.2006.02.004\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28XptFCguro%3D\" aria-label=\"CAS reference 12\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=16581033\" aria-label=\"PubMed reference 12\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 12\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Telomere%20shortening%20and%20mood%20disorders%3A%20preliminary%20support%20for%20a%20chronic%20stress%20model%20of%20accelerated%20aging\u0026amp;journal=Biol.%20Psychiatry\u0026amp;doi=10.1016%2Fj.biopsych.2006.02.004\u0026amp;volume=60\u0026amp;pages=432-435\u0026amp;publication_year=2006\u0026amp;author=Simon%2CNM\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"13.\"\u003e\u003cp id=\"ref-CR13\"\u003eOkereke, O. I. et al. High phobic anxiety is related to lower leukocyte telomere length in women. \u003ci\u003ePloS One\u003c/i\u003e \u003cb\u003e7\u003c/b\u003e, e40516 (2012).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1371/journal.pone.0040516\" data-track-item_id=\"10.1371/journal.pone.0040516\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1371%2Fjournal.pone.0040516\" aria-label=\"Article reference 13\" data-doi=\"10.1371/journal.pone.0040516\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhtVKrsr7E\" aria-label=\"CAS reference 13\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=22808180\" aria-label=\"PubMed reference 13\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394740\" aria-label=\"PubMed Central reference 13\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 13\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=High%20phobic%20anxiety%20is%20related%20to%20lower%20leukocyte%20telomere%20length%20in%20women\u0026amp;journal=PloS%20One\u0026amp;doi=10.1371%2Fjournal.pone.0040516\u0026amp;volume=7\u0026amp;publication_year=2012\u0026amp;author=Okereke%2COI\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"14.\"\u003e\u003cp id=\"ref-CR14\"\u003eHecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. \u003ci\u003eSci. Transl. Med.\u003c/i\u003e \u003cb\u003e6\u003c/b\u003e, 231ra247 (2014).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1126/scitranslmed.3008182\" data-track-item_id=\"10.1126/scitranslmed.3008182\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1126%2Fscitranslmed.3008182\" aria-label=\"Article reference 14\" data-doi=\"10.1126/scitranslmed.3008182\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 14\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Reversal%20of%20persistent%20fibrosis%20in%20aging%20by%20targeting%20Nox4-Nrf2%20redox%20imbalance\u0026amp;journal=Sci.%20Transl.%20Med.\u0026amp;doi=10.1126%2Fscitranslmed.3008182\u0026amp;volume=6\u0026amp;publication_year=2014\u0026amp;author=Hecker%2CL\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"15.\"\u003e\u003cp id=\"ref-CR15\"\u003eFadahunsi, N. et al. Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. \u003ci\u003eTransl. Psychiatry\u003c/i\u003e \u003cb\u003e12\u003c/b\u003e, 330 (2022).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1038/s41398-022-02103-9\" data-track-item_id=\"10.1038/s41398-022-02103-9\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1038%2Fs41398-022-02103-9\" aria-label=\"Article reference 15\" data-doi=\"10.1038/s41398-022-02103-9\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XitF2jt7%2FO\" aria-label=\"CAS reference 15\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=35953488\" aria-label=\"PubMed reference 15\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372155\" aria-label=\"PubMed Central reference 15\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 15\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Acute%20and%20long-term%20effects%20of%20psilocybin%20on%20energy%20balance%20and%20feeding%20behavior%20in%20mice\u0026amp;journal=Transl.%20Psychiatry\u0026amp;doi=10.1038%2Fs41398-022-02103-9\u0026amp;volume=12\u0026amp;publication_year=2022\u0026amp;author=Fadahunsi%2CN\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"16.\"\u003e\u003cp id=\"ref-CR16\"\u003eKarlsson, M. et al. A single-cell type transcriptomics map of human tissues. \u003ci\u003eSci. Adv.\u003c/i\u003e \u003cb\u003e7\u003c/b\u003e, eabh2169 (2021).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1126/sciadv.abh2169\" data-track-item_id=\"10.1126/sciadv.abh2169\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1126%2Fsciadv.abh2169\" aria-label=\"Article reference 16\" data-doi=\"10.1126/sciadv.abh2169\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXitVKkur%2FF\" aria-label=\"CAS reference 16\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=34321199\" aria-label=\"PubMed reference 16\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318366\" aria-label=\"PubMed Central reference 16\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 16\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=A%20single-cell%20type%20transcriptomics%20map%20of%20human%20tissues\u0026amp;journal=Sci.%20Adv.\u0026amp;doi=10.1126%2Fsciadv.abh2169\u0026amp;volume=7\u0026amp;publication_year=2021\u0026amp;author=Karlsson%2CM\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"17.\"\u003e\u003cp id=\"ref-CR17\"\u003eFanibunda, S. E. et al. Serotonin regulates mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT(2A) receptor and SIRT1-PGC-1alpha axis. \u003ci\u003eProc. Natl. Acad. Sci. USA\u003c/i\u003e \u003cb\u003e116\u003c/b\u003e, 11028–11037 (2019).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1073/pnas.1821332116\" data-track-item_id=\"10.1073/pnas.1821332116\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1073%2Fpnas.1821332116\" aria-label=\"Article reference 17\" data-doi=\"10.1073/pnas.1821332116\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVChsrvF\" aria-label=\"CAS reference 17\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=31072928\" aria-label=\"PubMed reference 17\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561197\" aria-label=\"PubMed Central reference 17\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 17\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Serotonin%20regulates%20mitochondrial%20biogenesis%20and%20function%20in%20rodent%20cortical%20neurons%20via%20the%205-HT%282A%29%20receptor%20and%20SIRT1-PGC-1alpha%20axis\u0026amp;journal=Proc.%20Natl.%20Acad.%20Sci.%20USA\u0026amp;doi=10.1073%2Fpnas.1821332116\u0026amp;volume=116\u0026amp;pages=11028-11037\u0026amp;publication_year=2019\u0026amp;author=Fanibunda%2CSE\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"18.\"\u003e\u003cp id=\"ref-CR18\"\u003eChen, C., Zhou, M., Ge, Y. \u0026amp; Wang, X. SIRT1 and aging related signaling pathways. \u003ci\u003eMech. Ageing Dev.\u003c/i\u003e \u003cb\u003e187\u003c/b\u003e, 111215 (2020).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.mad.2020.111215\" data-track-item_id=\"10.1016/j.mad.2020.111215\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.mad.2020.111215\" aria-label=\"Article reference 18\" data-doi=\"10.1016/j.mad.2020.111215\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXjvFWjur4%3D\" aria-label=\"CAS reference 18\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=32084459\" aria-label=\"PubMed reference 18\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 18\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=SIRT1%20and%20aging%20related%20signaling%20pathways\u0026amp;journal=Mech.%20Ageing%20Dev.\u0026amp;doi=10.1016%2Fj.mad.2020.111215\u0026amp;volume=187\u0026amp;publication_year=2020\u0026amp;author=Chen%2CC\u0026amp;author=Zhou%2CM\u0026amp;author=Ge%2CY\u0026amp;author=Wang%2CX\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"19.\"\u003e\u003cp id=\"ref-CR19\"\u003eInserra, A., Campanale, A., Rezai, T., Romualdi, P. \u0026amp; Rubino, T. Epigenetic mechanisms of rapid-acting antidepressants. \u003ci\u003eTransl. Psychiatry\u003c/i\u003e \u003cb\u003e14\u003c/b\u003e, 359 (2024).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1038/s41398-024-03055-y\" data-track-item_id=\"10.1038/s41398-024-03055-y\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1038%2Fs41398-024-03055-y\" aria-label=\"Article reference 19\" data-doi=\"10.1038/s41398-024-03055-y\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=39231927\" aria-label=\"PubMed reference 19\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375021\" aria-label=\"PubMed Central reference 19\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 19\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Epigenetic%20mechanisms%20of%20rapid-acting%20antidepressants\u0026amp;journal=Transl.%20Psychiatry\u0026amp;doi=10.1038%2Fs41398-024-03055-y\u0026amp;volume=14\u0026amp;publication_year=2024\u0026amp;author=Inserra%2CA\u0026amp;author=Campanale%2CA\u0026amp;author=Rezai%2CT\u0026amp;author=Romualdi%2CP\u0026amp;author=Rubino%2CT\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"20.\"\u003e\u003cp id=\"ref-CR20\"\u003ede la Fuente Revenga, M. et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. \u003ci\u003eCell Rep.\u003c/i\u003e \u003cb\u003e37\u003c/b\u003e, 109836 (2021).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.celrep.2021.109836\" data-track-item_id=\"10.1016/j.celrep.2021.109836\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.celrep.2021.109836\" aria-label=\"Article reference 20\" data-doi=\"10.1016/j.celrep.2021.109836\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=34686347\" aria-label=\"PubMed reference 20\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 20\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Prolonged%20epigenomic%20and%20synaptic%20plasticity%20alterations%20following%20single%20exposure%20to%20a%20psychedelic%20in%20mice\u0026amp;journal=Cell%20Rep.\u0026amp;doi=10.1016%2Fj.celrep.2021.109836\u0026amp;volume=37\u0026amp;publication_year=2021\u0026amp;author=Fuente%20Revenga%2CM\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"21.\"\u003e\u003cp id=\"ref-CR21\"\u003eInserra, A. et al. Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): impact on neurotropic, neurotrophic, and neuroplasticity signaling. \u003ci\u003eProg. Neuropsychopharmacol. Biol. Psychiatry\u003c/i\u003e \u003cb\u003e119\u003c/b\u003e, 110594 (2022).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.pnpbp.2022.110594\" data-track-item_id=\"10.1016/j.pnpbp.2022.110594\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.pnpbp.2022.110594\" aria-label=\"Article reference 21\" data-doi=\"10.1016/j.pnpbp.2022.110594\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xit1OnsLnF\" aria-label=\"CAS reference 21\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=35777526\" aria-label=\"PubMed reference 21\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 21\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Modulation%20of%20DNA%20methylation%20and%20protein%20expression%20in%20the%20prefrontal%20cortex%20by%20repeated%20administration%20of%20D-lysergic%20acid%20diethylamide%20%28LSD%29%3A%20impact%20on%20neurotropic%2C%20neurotrophic%2C%20and%20neuroplasticity%20signaling\u0026amp;journal=Prog.%20Neuropsychopharmacol.%20Biol.%20Psychiatry\u0026amp;doi=10.1016%2Fj.pnpbp.2022.110594\u0026amp;volume=119\u0026amp;publication_year=2022\u0026amp;author=Inserra%2CA\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"22.\"\u003e\u003cp id=\"ref-CR22\"\u003eJohnson, M. W., Griffiths, R. R., Hendricks, P. S. \u0026amp; Henningfield, J. E. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. \u003ci\u003eNeuropharmacology\u003c/i\u003e \u003cb\u003e142\u003c/b\u003e, 143–166 (2018).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.neuropharm.2018.05.012\" data-track-item_id=\"10.1016/j.neuropharm.2018.05.012\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.neuropharm.2018.05.012\" aria-label=\"Article reference 22\" data-doi=\"10.1016/j.neuropharm.2018.05.012\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtVyjsr3L\" aria-label=\"CAS reference 22\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=29753748\" aria-label=\"PubMed reference 22\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791528\" aria-label=\"PubMed Central reference 22\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 22\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=The%20abuse%20potential%20of%20medical%20psilocybin%20according%20to%20the%208%20factors%20of%20the%20Controlled%20Substances%20Act\u0026amp;journal=Neuropharmacology\u0026amp;doi=10.1016%2Fj.neuropharm.2018.05.012\u0026amp;volume=142\u0026amp;pages=143-166\u0026amp;publication_year=2018\u0026amp;author=Johnson%2CMW\u0026amp;author=Griffiths%2CRR\u0026amp;author=Hendricks%2CPS\u0026amp;author=Henningfield%2CJE\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"23.\"\u003e\u003cp id=\"ref-CR23\"\u003eHall, W. The need for publicly funded research on therapeutic use of psychedelic drugs. \u003ci\u003eWorld Psychiatry\u003c/i\u003e \u003cb\u003e20\u003c/b\u003e, 197–198 (2021).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1002/wps.20847\" data-track-item_id=\"10.1002/wps.20847\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1002%2Fwps.20847\" aria-label=\"Article reference 23\" data-doi=\"10.1002/wps.20847\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=34002493\" aria-label=\"PubMed reference 23\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129837\" aria-label=\"PubMed Central reference 23\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 23\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=The%20need%20for%20publicly%20funded%20research%20on%20therapeutic%20use%20of%20psychedelic%20drugs\u0026amp;journal=World%20Psychiatry\u0026amp;doi=10.1002%2Fwps.20847\u0026amp;volume=20\u0026amp;pages=197-198\u0026amp;publication_year=2021\u0026amp;author=Hall%2CW\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"24.\"\u003e\u003cp id=\"ref-CR24\"\u003ePalitsky, R., et al. A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers. \u003ci\u003ePsychotherapy (Chic)\u003c/i\u003e (2025).\u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"25.\"\u003e\u003cp id=\"ref-CR25\"\u003eHasler, F., Grimberg, U., Benz, M. A., Huber, T. \u0026amp; Vollenweider, F. X. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study. \u003ci\u003ePsychopharmacology\u003c/i\u003e \u003cb\u003e172\u003c/b\u003e, 145–156 (2004).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"noopener\" data-track-label=\"10.1007/s00213-003-1640-6\" data-track-item_id=\"10.1007/s00213-003-1640-6\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://link.springer.com/doi/10.1007/s00213-003-1640-6\" aria-label=\"Article reference 25\" data-doi=\"10.1007/s00213-003-1640-6\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2cXhsFyktb8%3D\" aria-label=\"CAS reference 25\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=14615876\" aria-label=\"PubMed reference 25\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 25\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Acute%20psychological%20and%20physiological%20effects%20of%20psilocybin%20in%20healthy%20humans%3A%20a%20double-blind%2C%20placebo-controlled%20dose%E2%80%93effect%20study\u0026amp;journal=Psychopharmacology\u0026amp;doi=10.1007%2Fs00213-003-1640-6\u0026amp;volume=172\u0026amp;pages=145-156\u0026amp;publication_year=2004\u0026amp;author=Hasler%2CF\u0026amp;author=Grimberg%2CU\u0026amp;author=Benz%2CMA\u0026amp;author=Huber%2CT\u0026amp;author=Vollenweider%2CFX\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"26.\"\u003e\u003cp id=\"ref-CR26\"\u003eJohnson, M. W., Richards, W. A. \u0026amp; Griffiths, R. R. Human hallucinogen research: guidelines for safety. \u003ci\u003eJ. Psychopharmacol.\u003c/i\u003e \u003cb\u003e22\u003c/b\u003e, 603–620 (2008).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1177/0269881108093587\" data-track-item_id=\"10.1177/0269881108093587\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1177%2F0269881108093587\" aria-label=\"Article reference 26\" data-doi=\"10.1177/0269881108093587\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXjtVyhsLk%3D\" aria-label=\"CAS reference 26\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=18593734\" aria-label=\"PubMed reference 26\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056407\" aria-label=\"PubMed Central reference 26\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 26\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Human%20hallucinogen%20research%3A%20guidelines%20for%20safety\u0026amp;journal=J.%20Psychopharmacol.\u0026amp;doi=10.1177%2F0269881108093587\u0026amp;volume=22\u0026amp;pages=603-620\u0026amp;publication_year=2008\u0026amp;author=Johnson%2CMW\u0026amp;author=Richards%2CWA\u0026amp;author=Griffiths%2CRR\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"27.\"\u003e\u003cp id=\"ref-CR27\"\u003eGrinspoon, L. \u0026amp; Bakalar, J. B. Can drugs be used to enhance the psychotherapeutic process?. \u003ci\u003eAm. J. Psychother.\u003c/i\u003e \u003cb\u003e40\u003c/b\u003e, 393–404 (1986).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1176/appi.psychotherapy.1986.40.3.393\" data-track-item_id=\"10.1176/appi.psychotherapy.1986.40.3.393\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1176%2Fappi.psychotherapy.1986.40.3.393\" aria-label=\"Article reference 27\" data-doi=\"10.1176/appi.psychotherapy.1986.40.3.393\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:STN:280:DyaL2s%2FitlGjsA%3D%3D\" aria-label=\"CAS reference 27\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=2876654\" aria-label=\"PubMed reference 27\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 27\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Can%20drugs%20be%20used%20to%20enhance%20the%20psychotherapeutic%20process%3F\u0026amp;journal=Am.%20J.%20Psychother.\u0026amp;doi=10.1176%2Fappi.psychotherapy.1986.40.3.393\u0026amp;volume=40\u0026amp;pages=393-404\u0026amp;publication_year=1986\u0026amp;author=Grinspoon%2CL\u0026amp;author=Bakalar%2CJB\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"28.\"\u003e\u003cp id=\"ref-CR28\"\u003eAaronson, B. S. \u0026amp; Osmond, H. \u003ci\u003ePsychedelics:\u003c/i\u003e \u003ci\u003ethe uses and implications of hallucinogenic drugs\u003c/i\u003e (Doubleday Garden City, 1970).\u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"29.\"\u003e\u003cp id=\"ref-CR29\"\u003eTyls, F. et al. Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. \u003ci\u003eBehav. Pharm.\u003c/i\u003e \u003cb\u003e27\u003c/b\u003e, 309–320 (2016).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1097/FBP.0000000000000198\" data-track-item_id=\"10.1097/FBP.0000000000000198\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1097%2FFBP.0000000000000198\" aria-label=\"Article reference 29\" data-doi=\"10.1097/FBP.0000000000000198\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XmvVKltLc%3D\" aria-label=\"CAS reference 29\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 29\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Sex%20differences%20and%20serotonergic%20mechanisms%20in%20the%20behavioural%20effects%20of%20psilocin\u0026amp;journal=Behav.%20Pharm.\u0026amp;doi=10.1097%2FFBP.0000000000000198\u0026amp;volume=27\u0026amp;pages=309-320\u0026amp;publication_year=2016\u0026amp;author=Tyls%2CF\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"30.\"\u003e\u003cp id=\"ref-CR30\"\u003eEffinger, D. P., Quadir, S. G., Ramage, M. C., Cone, M. G. \u0026amp; Herman, M. A. Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. \u003ci\u003eTransl. Psychiatry\u003c/i\u003e \u003cb\u003e13\u003c/b\u003e, 119 (2023).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1038/s41398-023-02414-5\" data-track-item_id=\"10.1038/s41398-023-02414-5\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1038%2Fs41398-023-02414-5\" aria-label=\"Article reference 30\" data-doi=\"10.1038/s41398-023-02414-5\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXntlKjtro%3D\" aria-label=\"CAS reference 30\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=37031219\" aria-label=\"PubMed reference 30\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082812\" aria-label=\"PubMed Central reference 30\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 30\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Sex-specific%20effects%20of%20psychedelic%20drug%20exposure%20on%20central%20amygdala%20reactivity%20and%20behavioral%20responding\u0026amp;journal=Transl.%20Psychiatry\u0026amp;doi=10.1038%2Fs41398-023-02414-5\u0026amp;volume=13\u0026amp;publication_year=2023\u0026amp;author=Effinger%2CDP\u0026amp;author=Quadir%2CSG\u0026amp;author=Ramage%2CMC\u0026amp;author=Cone%2CMG\u0026amp;author=Herman%2CMA\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"31.\"\u003e\u003cp id=\"ref-CR31\"\u003eShao, L. X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. \u003ci\u003eNeuron\u003c/i\u003e \u003cb\u003e109\u003c/b\u003e, 2535–2544 e2534 (2021).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.neuron.2021.06.008\" data-track-item_id=\"10.1016/j.neuron.2021.06.008\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.neuron.2021.06.008\" aria-label=\"Article reference 31\" data-doi=\"10.1016/j.neuron.2021.06.008\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsVOrsrrM\" aria-label=\"CAS reference 31\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=34228959\" aria-label=\"PubMed reference 31\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376772\" aria-label=\"PubMed Central reference 31\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 31\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Psilocybin%20induces%20rapid%20and%20persistent%20growth%20of%20dendritic%20spines%20in%20frontal%20cortex%20in%20vivo\u0026amp;journal=Neuron\u0026amp;doi=10.1016%2Fj.neuron.2021.06.008\u0026amp;volume=109\u0026amp;pages=2535-2544%20e2534\u0026amp;publication_year=2021\u0026amp;author=Shao%2CLX\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"32.\"\u003e\u003cp id=\"ref-CR32\"\u003eNair, A. B. \u0026amp; Jacob, S. A simple practice guide for dose conversion between animals and human. \u003ci\u003eJ. Basic Clin. Pharm.\u003c/i\u003e \u003cb\u003e7\u003c/b\u003e, 27–31 (2016).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.4103/0976-0105.177703\" data-track-item_id=\"10.4103/0976-0105.177703\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.4103%2F0976-0105.177703\" aria-label=\"Article reference 32\" data-doi=\"10.4103/0976-0105.177703\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=27057123\" aria-label=\"PubMed reference 32\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804402\" aria-label=\"PubMed Central reference 32\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 32\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=A%20simple%20practice%20guide%20for%20dose%20conversion%20between%20animals%20and%20human\u0026amp;journal=J.%20Basic%20Clin.%20Pharm.\u0026amp;doi=10.4103%2F0976-0105.177703\u0026amp;volume=7\u0026amp;pages=27-31\u0026amp;publication_year=2016\u0026amp;author=Nair%2CAB\u0026amp;author=Jacob%2CS\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"33.\"\u003e\u003cp id=\"ref-CR33\"\u003eThomann, J. et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. \u003ci\u003eFront. Pharm.\u003c/i\u003e \u003cb\u003e15\u003c/b\u003e, 1391689 (2024).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.3389/fphar.2024.1391689\" data-track-item_id=\"10.3389/fphar.2024.1391689\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.3389%2Ffphar.2024.1391689\" aria-label=\"Article reference 33\" data-doi=\"10.3389/fphar.2024.1391689\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXhtlGjs7bI\" aria-label=\"CAS reference 33\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 33\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=In%20vitro%20and%20in%20vivo%20metabolism%20of%20psilocybin%E2%80%99s%20active%20metabolite%20psilocin\u0026amp;journal=Front.%20Pharm.\u0026amp;doi=10.3389%2Ffphar.2024.1391689\u0026amp;volume=15\u0026amp;publication_year=2024\u0026amp;author=Thomann%2CJ\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"34.\"\u003e\u003cp id=\"ref-CR34\"\u003eHolze, F., Becker, A. M., Kolaczynska, K. E., Duthaler, U. \u0026amp; Liechti, M. E. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. \u003ci\u003eClin. Pharm. Ther.\u003c/i\u003e \u003cb\u003e113\u003c/b\u003e, 822–831 (2023).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1002/cpt.2821\" data-track-item_id=\"10.1002/cpt.2821\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1002%2Fcpt.2821\" aria-label=\"Article reference 34\" data-doi=\"10.1002/cpt.2821\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXns1Kisg%3D%3D\" aria-label=\"CAS reference 34\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 34\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Pharmacokinetics%20and%20pharmacodynamics%20of%20oral%20psilocybin%20administration%20in%20healthy%20participants\u0026amp;journal=Clin.%20Pharm.%20Ther.\u0026amp;doi=10.1002%2Fcpt.2821\u0026amp;volume=113\u0026amp;pages=822-831\u0026amp;publication_year=2023\u0026amp;author=Holze%2CF\u0026amp;author=Becker%2CAM\u0026amp;author=Kolaczynska%2CKE\u0026amp;author=Duthaler%2CU\u0026amp;author=Liechti%2CME\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"35.\"\u003e\u003cp id=\"ref-CR35\"\u003eZhuk, O. et al. Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice. \u003ci\u003eToxins\u003c/i\u003e\u003cb\u003e7\u003c/b\u003e, 1018–1029 (2015).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.3390/toxins7041018\" data-track-item_id=\"10.3390/toxins7041018\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.3390%2Ftoxins7041018\" aria-label=\"Article reference 35\" data-doi=\"10.3390/toxins7041018\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXnvFKntb0%3D\" aria-label=\"CAS reference 35\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=25826052\" aria-label=\"PubMed reference 35\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417952\" aria-label=\"PubMed Central reference 35\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 35\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Research%20on%20acute%20toxicity%20and%20the%20behavioral%20effects%20of%20methanolic%20extract%20from%20psilocybin%20mushrooms%20and%20psilocin%20in%20mice\u0026amp;journal=Toxins\u0026amp;doi=10.3390%2Ftoxins7041018\u0026amp;volume=7\u0026amp;pages=1018-1029\u0026amp;publication_year=2015\u0026amp;author=Zhuk%2CO\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"36.\"\u003e\u003cp id=\"ref-CR36\"\u003eDuan, F. et al. Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. \u003ci\u003eJ. Immunol. Methods\u003c/i\u003e \u003cb\u003e382\u003c/b\u003e, 224–228 (2012).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1016/j.jim.2012.06.005\" data-track-item_id=\"10.1016/j.jim.2012.06.005\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1016%2Fj.jim.2012.06.005\" aria-label=\"Article reference 36\" data-doi=\"10.1016/j.jim.2012.06.005\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XptlWqsro%3D\" aria-label=\"CAS reference 36\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=22698786\" aria-label=\"PubMed reference 36\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 36\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Area%20under%20the%20curve%20as%20a%20tool%20to%20measure%20kinetics%20of%20tumor%20growth%20in%20experimental%20animals\u0026amp;journal=J.%20Immunol.%20Methods\u0026amp;doi=10.1016%2Fj.jim.2012.06.005\u0026amp;volume=382\u0026amp;pages=224-228\u0026amp;publication_year=2012\u0026amp;author=Duan%2CF\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003cli data-counter=\"37.\"\u003e\u003cp id=\"ref-CR37\"\u003eFallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W. \u0026amp; Sorger, P. K. Metrics other than potency reveal systematic variation in responses to cancer drugs. \u003ci\u003eNat. Chem. Biol.\u003c/i\u003e \u003cb\u003e9\u003c/b\u003e, 708–714 (2013).\u003c/p\u003e\u003cp\u003e\u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"10.1038/nchembio.1337\" data-track-item_id=\"10.1038/nchembio.1337\" data-track-value=\"article reference\" data-track-action=\"article reference\" href=\"https://doi.org/10.1038%2Fnchembio.1337\" aria-label=\"Article reference 37\" data-doi=\"10.1038/nchembio.1337\"\u003eArticle\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"cas reference\" data-track-action=\"cas reference\" href=\"https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhtl2kt7vP\" aria-label=\"CAS reference 37\"\u003eCAS\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed reference\" data-track-action=\"pubmed reference\" href=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u0026amp;db=PubMed\u0026amp;dopt=Abstract\u0026amp;list_uids=24013279\" aria-label=\"PubMed reference 37\"\u003ePubMed\u003c/a\u003e \n    \u003ca data-track=\"click_references\" rel=\"nofollow noopener\" data-track-label=\"link\" data-track-item_id=\"link\" data-track-value=\"pubmed central reference\" data-track-action=\"pubmed central reference\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947796\" aria-label=\"PubMed Central reference 37\"\u003ePubMed Central\u003c/a\u003e \n    \u003ca data-track=\"click_references\" data-track-action=\"google scholar reference\" data-track-value=\"google scholar reference\" data-track-label=\"link\" data-track-item_id=\"link\" rel=\"nofollow noopener\" aria-label=\"Google Scholar reference 37\" href=\"http://scholar.google.com/scholar_lookup?\u0026amp;title=Metrics%20other%20than%20potency%20reveal%20systematic%20variation%20in%20responses%20to%20cancer%20drugs\u0026amp;journal=Nat.%20Chem.%20Biol.\u0026amp;doi=10.1038%2Fnchembio.1337\u0026amp;volume=9\u0026amp;pages=708-714\u0026amp;publication_year=2013\u0026amp;author=Fallahi-Sichani%2CM\u0026amp;author=Honarnejad%2CS\u0026amp;author=Heiser%2CLM\u0026amp;author=Gray%2CJW\u0026amp;author=Sorger%2CPK\"\u003e\n                    Google Scholar\u003c/a\u003e \n                \u003c/p\u003e\u003c/li\u003e\u003c/ol\u003e\u003cp\u003e\u003ca data-track=\"click\" data-track-action=\"download citation references\" data-track-label=\"link\" rel=\"nofollow\" href=\"https://citation-needed.springer.com/v2/references/10.1038/s41514-025-00244-x?format=refman\u0026amp;flavour=references\"\u003eDownload references\u003c/a\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Ack1-section\" data-title=\"Acknowledgements\"\u003e\u003ch2 id=\"Ack1\"\u003eAcknowledgements\u003c/h2\u003e\u003cp\u003eWe would like to acknowledge Aaron Clippinger for igniting our interest in psilocybin. Research reported in this publication was supported and made possible by the Imagine, Innovate and Impact (I\u003csup\u003e3\u003c/sup\u003e) Award from the Emory School of Medicine (LH and AJZ) and through the Georgia CTSA NIH award (UL1-TR002378), and a grant from the Emory Woodruff Health Sciences Center for Health in Aging (LH and AJZ). LH also received funding support for effort from the Veterans Administration Health System grant (BX006003). C.C. was partially supported by CPRIT RP210227 and RP200504, NIH/NCI P30 shared resource grant CA125123, NIH/NIEHS P42 ES027725 and P30 ES030285.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"author-information-section\" aria-labelledby=\"author-information\" data-title=\"Author information\"\u003e\u003ch2 id=\"author-information\"\u003eAuthor information\u003c/h2\u003e\u003cdiv id=\"author-information-content\"\u003e\u003ch3 id=\"affiliations\"\u003eAuthors and Affiliations\u003c/h3\u003e\u003col\u003e\u003cli id=\"Aff1\"\u003e\u003cp\u003eDivision of Pulmonary, Allergy and Critical Care and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USA\u003c/p\u003e\u003cp\u003eKosuke Kato, Jennifer M. Kleinhenz, Yoon-Joo Shin \u0026amp; Louise Hecker\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff2\"\u003e\u003cp\u003eSection of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA\u003c/p\u003e\u003cp\u003eKosuke Kato\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff3\"\u003e\u003cp\u003eDivision of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA\u003c/p\u003e\u003cp\u003eJennifer M. Kleinhenz \u0026amp; Louise Hecker\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff4\"\u003e\u003cp\u003eDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA\u003c/p\u003e\u003cp\u003eCristian Coarfa\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff5\"\u003e\u003cp\u003eDivision of Palliative Medicine, Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA, USA\u003c/p\u003e\u003cp\u003eAli J. Zarrabi\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff6\"\u003e\u003cp\u003eAtlanta VA Healthcare System, Atlanta, GA, USA\u003c/p\u003e\u003cp\u003eLouise Hecker\u003c/p\u003e\u003c/li\u003e\u003c/ol\u003e\u003cdiv data-test=\"author-info\"\u003e\u003cp\u003e\u003cspan\u003eAuthors\u003c/span\u003e\u003c/p\u003e\u003col\u003e\u003cli id=\"auth-Kosuke-Kato-Aff1-Aff2\"\u003e\u003cspan\u003eKosuke Kato\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Jennifer_M_-Kleinhenz-Aff1-Aff3\"\u003e\u003cspan\u003eJennifer M. Kleinhenz\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Yoon_Joo-Shin-Aff1\"\u003e\u003cspan\u003eYoon-Joo Shin\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Cristian-Coarfa-Aff4\"\u003e\u003cspan\u003eCristian Coarfa\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Ali_J_-Zarrabi-Aff5\"\u003e\u003cspan\u003eAli J. Zarrabi\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Louise-Hecker-Aff1-Aff3-Aff6\"\u003e\u003cspan\u003eLouise Hecker\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e\u003c/div\u003e\u003ch3 id=\"contributions\"\u003eContributions\u003c/h3\u003e\u003cp\u003eL.H. conceived the project, supervised all studies, and drafted the manuscript. L.H., K.K., Y.J.S., and J.M.K. designed, conducted, and/or performed analyses for experiments. C.C. contributed to the statistical analyses. All authors contributed intellectual input to the overall project and with manuscript/figure preparation.\u003c/p\u003e\u003ch3 id=\"corresponding-author\"\u003eCorresponding author\u003c/h3\u003e\u003cp id=\"corresponding-author-list\"\u003eCorrespondence to\n                \u003ca id=\"corresp-c1\" href=\"mailto:louise.hecker@bcm.edu\"\u003eLouise Hecker\u003c/a\u003e.\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"ethics-section\" data-title=\"Ethics declarations\"\u003e\u003ch2 id=\"ethics\"\u003eEthics declarations\u003c/h2\u003e\u003cdiv id=\"ethics-content\"\u003e\n              \n                \u003ch3 id=\"FPar1\"\u003eCompeting interests\u003c/h3\u003e\n                \u003cp\u003eThe authors declare no competing interests.\u003c/p\u003e\n              \n            \u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"additional-information-section\" data-title=\"Additional information\"\u003e\u003ch2 id=\"additional-information\"\u003eAdditional information\u003c/h2\u003e\u003cp\u003e\u003cb\u003ePublisher’s note\u003c/b\u003e Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec12-section\" data-title=\"Supplementary information\"\u003e\u003ch2 id=\"Sec12\"\u003eSupplementary information\u003c/h2\u003e\u003c/div\u003e\u003cdiv id=\"rightslink-section\" data-title=\"Rights and permissions\"\u003e\u003ch2 id=\"rightslink\"\u003eRights and permissions\u003c/h2\u003e\u003cdiv id=\"rightslink-content\"\u003e\n                \u003cp\u003e\u003cb\u003eOpen Access\u003c/b\u003e  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit \u003ca href=\"http://creativecommons.org/licenses/by/4.0/\" rel=\"license\"\u003ehttp://creativecommons.org/licenses/by/4.0/\u003c/a\u003e.\u003c/p\u003e\n              \u003cp\u003e\u003ca data-track=\"click\" data-track-action=\"view rights and permissions\" data-track-label=\"link\" href=\"https://s100.copyright.com/AppDispatchServlet?title=Psilocybin%20treatment%20extends%20cellular%20lifespan%20and%20improves%20survival%20of%20aged%20mice\u0026amp;author=Kosuke%20Kato%20et%20al\u0026amp;contentID=10.1038%2Fs41514-025-00244-x\u0026amp;copyright=This%20is%20a%20U.S.%20Government%20work%20and%20not%20under%20copyright%20protection%20in%20the%20US%3B%20foreign%20copyright%20protection%20may%20apply\u0026amp;publication=2731-6068\u0026amp;publicationDate=2025-07-08\u0026amp;publisherName=SpringerNature\u0026amp;orderBeanReset=true\u0026amp;oa=CC%20BY\"\u003eReprints and permissions\u003c/a\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"article-info-section\" aria-labelledby=\"article-info\" data-title=\"About this article\"\u003e\u003ch2 id=\"article-info\"\u003eAbout this article\u003c/h2\u003e\u003cdiv id=\"article-info-content\"\u003e\u003cp\u003e\u003ca data-crossmark=\"10.1038/s41514-025-00244-x\" target=\"_blank\" rel=\"noopener\" href=\"https://crossmark.crossref.org/dialog/?doi=10.1038/s41514-025-00244-x\" data-track=\"click\" data-track-action=\"Click Crossmark\" data-track-label=\"link\" data-test=\"crossmark\"\u003e\u003cimg loading=\"lazy\" width=\"57\" height=\"81\" alt=\"Check for updates. Verify currency and authenticity via CrossMark\" src=\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\"/\u003e\u003c/a\u003e\u003c/p\u003e\u003cdiv\u003e\u003ch3 id=\"citeas\"\u003eCite this article\u003c/h3\u003e\u003cp\u003eKato, K., Kleinhenz, J.M., Shin, YJ. \u003ci\u003eet al.\u003c/i\u003e Psilocybin treatment extends cellular lifespan and improves survival of aged mice.\n                    \u003ci\u003enpj Aging\u003c/i\u003e \u003cb\u003e11\u003c/b\u003e, 55 (2025). https://doi.org/10.1038/s41514-025-00244-x\u003c/p\u003e\u003cp\u003e\u003ca data-test=\"citation-link\" data-track=\"click\" data-track-action=\"download article citation\" data-track-label=\"link\" data-track-external=\"\" rel=\"nofollow\" href=\"https://citation-needed.springer.com/v2/references/10.1038/s41514-025-00244-x?format=refman\u0026amp;flavour=citation\"\u003eDownload citation\u003c/a\u003e\u003c/p\u003e\u003cul data-test=\"publication-history\"\u003e\u003cli\u003e\u003cp\u003eReceived\u003cspan\u003e: \u003c/span\u003e\u003cspan\u003e\u003ctime datetime=\"2024-12-09\"\u003e09 December 2024\u003c/time\u003e\u003c/span\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eAccepted\u003cspan\u003e: \u003c/span\u003e\u003cspan\u003e\u003ctime datetime=\"2025-06-02\"\u003e02 June 2025\u003c/time\u003e\u003c/span\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003ePublished\u003cspan\u003e: \u003c/span\u003e\u003cspan\u003e\u003ctime datetime=\"2025-07-08\"\u003e08 July 2025\u003c/time\u003e\u003c/span\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cabbr title=\"Digital Object Identifier\"\u003eDOI\u003c/abbr\u003e\u003cspan\u003e: \u003c/span\u003e\u003cspan\u003ehttps://doi.org/10.1038/s41514-025-00244-x\u003c/span\u003e\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\n            \u003c/div\u003e\u003c/div\u003e",
  "readingTime": "36 min read",
  "publishedTime": null,
  "modifiedTime": null
}
